[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 780
1. Bongiovanni M, Gremaud M, Moulin CS, Scheidegger C, Biton C, Clément S: Macrofollicular variant of follicular thyroid carcinoma: a clinical, cytologic, morphologic, and image analysis study of a unique case. Ann Diagn Pathol; 2009 Apr;13(2):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrofollicular variant of follicular thyroid carcinoma: a clinical, cytologic, morphologic, and image analysis study of a unique case.
  • Thyroid lesions composed of large follicles that contain abundant colloid are usually regarded as benign hyperplastic or adenomatous nodules both by fine-needle aspiration cytology and histology.
  • In such cases, the pathologist is less likely to request a complete inclusion of the capsule into paraffin block and to look for vascular and/or capsular invasion, the only criteria that permit the differential diagnosis between a benign nodule and a follicular carcinoma.
  • We report the first case of a follicular thyroid carcinoma composed predominantly (>90%) of macrofollicles with a surface area that was up to 5 times larger than the surface area of normal follicles, as calculated with an image analysis system.
  • The tumor was classified as a minimally invasive follicular carcinoma, macrofollicular variant.
  • This case is detailed to highlight the potential pitfall that may arise from an incomplete histological analysis of a macrofollicular lesion, with particular attention paid to the differential diagnoses.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Adult. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Image Interpretation, Computer-Assisted. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302958.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Uchida N, Suda T, Inoue T, Fujiwara Y, Ishiguro K: Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case. Surg Today; 2007;37(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case.
  • Few reports have been concerned with the risk of needle track dissemination of tumor cells following fine-needle aspiration biopsy, especially for follicular thyroid nodules.
  • A 61-year-old woman who underwent fine-needle aspiration biopsy and surgery 5 years previously for follicular thyroid adenoma presented with nodules that had developed in the sternocleidomastoid and omohyoid muscles of the anterior neck.
  • Following surgical resection, histological diagnosis determined the nodules to be follicular carcinoma.
  • The clinical course and linear arrangement of the lesions were highly suggestive of needle track dissemination of tumor cells following fine-needle aspiration biopsy.
  • Although fine-needle aspiration biopsy is a useful tool for the diagnosis of thyroid nodules, it is important to consider the risk of tumor cell dissemination.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biopsy, Fine-Needle / adverse effects. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Seeding. Thyroid Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Thyroid Gland / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Dec;29(12):1544-9 [16311845.001]
  • [Cites] N Engl J Med. 1989 Mar 30;320(13):835-40 [2927450.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Acta Radiol. 2000 Sep;41(5):435-40 [11016762.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):591-5 [12040660.001]
  • [Cites] Monogr Pathol. 1993;(35):166-99 [8502250.001]
  • [Cites] Thyroid. 1994 Fall;4(3):319-26 [7833670.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):710-5 [8782212.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):104-7 [11044522.001]
  • [Cites] Diagn Cytopathol. 1994;10(2):156-8 [8187596.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):168-72 [7898112.001]
  • [Cites] ANZ J Surg. 2003 Jul;73(7):480-3 [12864820.001]
  • [Cites] Acta Cytol. 1990 Nov-Dec;34(6):801-4 [2256415.001]
  • [Cites] Curr Treat Options Oncol. 2002 Aug;3(4):349-54 [12074771.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Mar;83(3):780-3 [9506726.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):505-24 [11169933.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):241-3 [9659269.001]
  • (PMID = 17186343.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Han KH, Croker BP, Clapp WL, Werner D, Sahni M, Kim J, Kim HY, Handlogten ME, Weiner ID: Expression of the ammonia transporter, rh C glycoprotein, in normal and neoplastic human kidney. J Am Soc Nephrol; 2006 Oct;17(10):2670-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have identified the presence of a novel Mep/Amt/Rh glycoprotein family of proteins that may play an important role in transmembrane ammonia transport.
  • One of the mammalian members of this family, Rh C glycoprotein (RhCG), transports ammonia, is expressed in distal nephron sites that are critically important for ammonia secretion, exhibits increased expression in response to chronic metabolic acidosis, and originally was cloned as a tumor-related protein.
  • Furthermore, renal chromophobe renal cell carcinoma and renal oncocytoma seem to originate from the A-type intercalated cell.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928804.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK045788; United States / NIDDK NIH HHS / DK / DK 45788; United States / NINDS NIH HHS / NS / R21 NS047624; United States / NIDDK NIH HHS / DK / R01 DK045788; United States / Intramural VA / / RR1 BX0001; United States / NINDS NIH HHS / NS / NS 47624
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / CALB1 protein, human; 0 / Calb1 protein, mouse; 0 / Calbindin 1; 0 / Calbindins; 0 / Cation Transport Proteins; 0 / Membrane Glycoproteins; 0 / Membrane Transport Proteins; 0 / RHCG protein, human; 0 / S100 Calcium Binding Protein G; 0 / SLC26A4 protein, human; 7664-41-7 / Ammonia; EC 3.6.3.14 / Proton-Translocating ATPases
  • [Other-IDs] NLM/ NIHMS478329; NLM/ PMC4319185
  •  go-up   go-down


Advertisement
4. Hoftijzer HC, Liu YY, Morreau H, van Wezel T, Pereira AM, Corssmit EP, Romijn JA, Smit JW: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol; 2009 Apr;160(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms.
  • BACKGROUND: Although differential expression of retinoic acid receptor (RAR) subtypes between benign and malignant thyroid tissues has been described, their diagnostic value has not been reported.
  • AIM: To investigate the diagnostic accuracy of RAR and retinoid X receptor (RXR) subtype protein expression for the differential diagnosis of thyroid neoplasms.
  • METHODS: We used a tissue array containing 93 benign thyroid tissues (normal thyroid, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • RESULTS: We found increased expression of cytoplasmic (c) RARA, cRARG, cRXRB and decreased expression of nuclear (n) RARB, nRARG, and nRXRA in thyroid carcinomas compared with benign tissues.
  • Using cluster analysis, the combination of negative staining of membranous RXRB and positive staining for cRXRB had a high positive predictive value (98%) for malignant thyroid disease, whereas the combination of positive nRXRA and negative cRXRB staining had a high predictive value (91%) for benign thyroid lesions.
  • CONCLUSION: We conclude that differences in RAR and RXR subtype protein expression may be valuable for the differential diagnosis of thyroid neoplasms.
  • The results of this study and especially the value of cluster analysis have to be confirmed in subsequent studies.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155317.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors
  •  go-up   go-down


5. Jarząb M, Lange D: Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study. Thyroid Res; 2009 Apr 08;2(1):5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The immunohistochemical study was performed on paraffin-embedded specimens of surgically resected thyroid tissue from 97 patients with thyroid diseases: 65 patients with papillary carcinoma (PTC), 11 patients with nodular goiter in whom features of benign papillary hyperplasia were found, 9 with lymphocytic thyroiditis (LT), 8 with follicular adenoma, and 4 patients with follicular carcinoma.
  • Significant correlation between EABA in primary PTC tumor and EABA in lymph node metastases was stated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Apr 6;38(14):4252-8 [10194342.001]
  • [Cites] Histopathology. 1997 Nov;31(5):400-7 [9416479.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2002 Dec;31(6):491-6 [12622897.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 18;247(2):312-4 [9642122.001]
  • [Cites] Histochemistry. 1985;83(4):325-30 [2415495.001]
  • [Cites] J Histochem Cytochem. 1981 Oct;29(10):1196-204 [7028859.001]
  • [Cites] Arch Med Res. 2002 Sep-Oct;33(5):439-47 [12459313.001]
  • [Cites] J Nutr Biochem. 2005 Jul;16(7):441-5 [15992688.001]
  • [Cites] Clin Chim Acta. 1996 Nov 15;255(1):1-11 [8930409.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1592-600 [16949643.001]
  • [Cites] J Nutr Biochem. 2005 Jul;16(7):432-4 [15992685.001]
  • [Cites] J Clin Pathol. 1984 Feb;37(2):223-5 [6198343.001]
  • [Cites] Mod Pathol. 1997 May;10(5):515-9 [9160320.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] Histochem J. 2002 Mar-Apr;34(3-4):97-103 [12495214.001]
  • [Cites] J Nutr Biochem. 2005 Jul;16(7):419-23 [15992682.001]
  • [Cites] Am J Vet Res. 1993 Jul;54(7):1177-82 [8368617.001]
  • [Cites] J Nutr. 2001 Jul;131(7):1909-13 [11435506.001]
  • (PMID = 19351422.001).
  • [ISSN] 1756-6614
  • [Journal-full-title] Thyroid research
  • [ISO-abbreviation] Thyroid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678080
  •  go-up   go-down


6. Xue WC, Hui YZ: [Problems in the diagnosis of thyroid papillary and follicular carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):220-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problems in the diagnosis of thyroid papillary and follicular carcinoma].
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Thyroid Gland / pathology. Thyroid Nodule / diagnosis. Thyroiditis / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706110.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Takano T, Yamada H: Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. Endocr J; 2009;56(1):9-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma.
  • Since the introduction of fine needle aspiration biopsy (FNAB) in the 1970's, a preoperative diagnostic technique for thyroid follicular carcinoma has long been awaited.
  • Many markers that distinguish follicular carcinomas from adenomas have been reported; however, most of them have not been confirmed to be beneficial for clinical use.
  • Several groups have reported that the suppression of TFF3 mRNA expression is related to malignant characteristics of thyroid follicular cell-derived tumors and the expression level of TFF3 mRNA is the most promising indicator for diagnosing follicular carcinoma.
  • Development of TFF3-based diagnostic methods is now ongoing and it may not be long before thyroid follicular carcinoma can be diagnosed preoperatively using an aspirated sample from the tumor.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Peptides / physiology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Adenoma / pathology. Adenoma / surgery. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Models, Biological. Preoperative Care / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506086.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / TFF3 protein, human
  • [Number-of-references] 48
  •  go-up   go-down


9. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M: Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol; 2009 Feb;16(2):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TSHR mRNA levels were correlated to thyroglobulin (Tg), imaging studies, and disease status during follow-up.
  • Thirty-four patients underwent 20 +/- 14 months median follow-up for papillary (n = 31, 91%), follicular (n = 2) or Hurthle cell (n = 1) TC.
  • Advanced-stage disease occurred in 24% at presentation, and 11 (32%) developed cervical node metastases or recurrence requiring reoperation during follow-up.
  • TSHR mRNA missed disease in 21% patients, but was better than Tg in 27%, including all those with Tg antibodies.
  • TSHR mRNA concurred with whole-body scan detectable disease for 11/14 patients (79%) and accurately predicted overall TC disease status in 77% patients.
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cell Differentiation. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroglobulin / genetics. Thyroglobulin / immunology. Thyroidectomy. Thyrotropin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015922.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


10. Terris DJ, Gourin CG, Chin E: Minimally invasive thyroidectomy: basic and advanced techniques. Laryngoscope; 2006 Mar;116(3):350-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We advocate at least two distinct approaches, depending on the disease process and multiple patient factors.
  • The most common diagnosis was follicular or Hürthle cell adenoma (29%), followed by papillary or follicular cancer (26%).
  • The majority of patients had follicular adenoma (42.9%) or papillary carcinoma (21.4%) as their primary diagnosis.
  • The choice of approach depends on a number of patient and disease factors.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Minimally Invasive Surgical Procedures. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540887.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tena-Suck ML, Salinas-Lara C, Sánchez-García A, Rembao-Bojórquez D, Ortiz-Plata A: Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma. Surg Neurol; 2006 Nov;66(5):527-33; discussion 533
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial dissemination of pituitary adenomas is a rare event that does not equate malignancy.
  • A case of papillary pituitary carcinoma developed 12 years after radiotherapy for prolactin-secreting hormone pituitary adenoma is presented.
  • The patient underwent a craniotomy and biopsy of the lesion that was consistent with pituitary carcinoma; it was immunoreactive to follicle-stimulating hormone, adrenocorticotropic hormone, pituitary tumor-transforming gene, and epithelial cell adhesion molecule.
  • Transmission electron microscopy analysis confirmed the secretory pituitary tumor diagnosis.
  • CONCLUSIONS: The tumor was considered a primary pituitary papillary carcinoma.
  • The clinical course indicated that this tumor was the seedling of a pituitary tumor, although it could be interpreted as metastases from a pituitary carcinoma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Disease Progression. Fatal Outcome. Female. Humans. Lactotrophs / pathology. Lactotrophs / radiation effects. Lateral Ventricles / pathology. Neoplasm Invasiveness. Neoplasm, Residual. Pituitary Gland / metabolism. Pituitary Gland / pathology. Pituitary Gland / radiation effects. Time. Time Factors

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084204.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Dewil B, Van Damme B, Vander Poorten V, Delaere P, Debruyne F: Completion thyroidectomy after the unexpected diagnosis of thyroid cancer. B-ENT; 2005;1(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / radionuclide imaging. Thyroid Gland / ultrasonography. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044737.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


13. Cavaco BM, Batista PF, Martins C, Banito A, do Rosário F, Limbert E, Sobrinho LG, Leite V: Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer; 2008 Mar;15(1):207-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 8 FNMTC families, and 27 thyroid lesions from family members (22 papillary thyroid carcinomas (PTCs): 11 classic, 10 of the follicular variant and 1 of the mixed variant; 4 follicular thyroid adenomas (FTAs) and 1 nodular goitre (NG)), were evaluated for the involvement of the four susceptibility regions, using linkage and loss of heterozygosity (LOH) analyses.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Carcinoma, Papillary / genetics. Genes, ras / genetics. Genetic Linkage. Goiter, Nodular / genetics. Mutation / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Lod Score. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310288.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


14. Tajiri J: [Approach to thyroid incidentaloma and follicular adenoma]. Nihon Rinsho; 2007 Nov;65(11):2099-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Approach to thyroid incidentaloma and follicular adenoma].
  • Secondly, I describe the differential diagnosis of follicular adenoma and follicular carcinoma that we should call the last fort of thyroid medical practice.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Adenoma / diagnosis. Adenoma / therapy. Incidental Findings. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018577.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  • [Number-of-references] 39
  •  go-up   go-down


15. Camargo RS, Shirata NK, di Loreto C, Garcia EA, Castelo A, Longatto Filho A: Significance of AgNOR measurement in thyroid lesions. Anal Quant Cytol Histol; 2006 Aug;28(4):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases studied included 3 goiters, 10 follicular adenomas, 6 Hürthle adenomas, 4 follicular carcinomas, 7 papillary carcinomas, and 3 Hürthle carcinomas.
  • For statistical purposes, lesions were classified as benign and malignant, and both the number and the area of counted NORs showed very similar values.
  • The NORs median among 19 benign tumors was 1.484 (SD +/- 0.265) and of 14 malignant tumors was 1.436 (SD +/- 0.414); the NORs areas were 2.6584 (SD +/- 1.0653) and 2.3643 (SD +/- 0.6320), respectively.
  • CONCLUSION: Our results showed that AgNOR evaluation was not a significant parameter to discriminate between malignant and benign thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927638.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Menon MP, Khan A: Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol; 2009 Nov;62(11):978-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micro-RNAs (miRNAs) belong to a class of small non-coding messenger RNA species that have emerged as potent regulators of a variety of biological processes including oncogenesis.
  • Currently, a considerable degree of interobserver variability exists in the morphological diagnosis of certain types of thyroid carcinomas especially the follicular pattern neoplasm.
  • In this context, miRNAs serve as an important diagnostic tool, and several studies have demonstrated their utility as class identifiers especially in the context of follicular thyroid carcinoma, papillary thyroid carcinoma and anaplastic thyroid carcinoma.
  • [MeSH-major] MicroRNAs / genetics. RNA, Neoplasm / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / genetics. Adenoma / diagnosis. Adenoma / genetics. Carcinoma / diagnosis. Carcinoma / genetics. Cell Differentiation / genetics. Diagnosis, Differential. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625289.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm
  • [Number-of-references] 93
  •  go-up   go-down


17. Phitayakorn R, McHenry CR: Follicular and Hürthle cell carcinoma of the thyroid gland. Surg Oncol Clin N Am; 2006 Jul;15(3):603-23, ix-x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular and Hürthle cell carcinoma of the thyroid gland.
  • Follicular and Hürthle cell carcinoma of the thyroid gland are uncommon tumors that are genotypically similar.
  • Current and future diagnostic adjuncts, treatment, and postoperative follow-up for patients with follicular and Hürthle cell cancer are outlined.
  • Risk factors for recurrence and mortality and the reported outcomes of treatment of follicular and Hürthle cell carcinoma are reviewed.
  • [MeSH-major] Adenoma, Oxyphilic. Thyroid Neoplasms
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Humans. Iodine Radioisotopes. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroidectomy. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882500.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 92
  •  go-up   go-down


18. Garg M, Kanojia D, Suri S, Gupta S, Gupta A, Suri A: Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab; 2009 Nov;94(11):4613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Cancer-testis antigens are the unique class of testis proteins expressed in tumor but not healthy tissue except testis and might represent ideal targets for the development of novel diagnostics and therapeutic methods in thyroid cancer, which is the most common malignancy of the endocrine system.
  • DESIGN, SETTING, AND SUBJECTS: SPAG9 gene and protein expression was determined in thyroid cancer cell lines in 138 thyroid tumor specimens, 60 adjacent noncancerous tissues (ANCT), 22 multinodular goiters (nonneoplastic hyperplasia), and 20 follicular adenoma tissue samples by RT-PCR, in situ RNA hybridization, and immunohistochemistry.
  • RESULTS: SPAG9 mRNA and protein expression was detected in 78% of the thyroid cancer patients but not multiple goiters and follicular adenoma disease patients.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Neoplastic. Goiter / blood. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820019.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SPAG9 protein, human
  •  go-up   go-down


19. Ghossein R: Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol; 2010 Dec;21(4):212-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated malignant follicular cell-derived thyroid tumors.
  • Encapsulated malignant follicular cell-derived thyroid tumors are subject to considerable controversies.
  • This group includes encapsulated follicular variant of papillary carcinoma (FVPTC) and encapsulated (so-called minimally invasive) follicular carcinoma (EFC).
  • FVPTC usually presents as an encapsulated tumor and less commonly as a partially/nonencapsulated infiltrative neoplasm.
  • Encapsulated FVPTC have a molecular profile very close to follicular adenomas/carcinomas (high rate of RAS and absence of BRAF mutations).
  • Infiltrative follicular variant has an opposite molecular profile closer to classical papillary thyroid carcinoma than to follicular adenoma/carcinoma (BRAF > RAS mutations).
  • Encapsulated FVPTC have a molecular profile and a clinical behavior very similar to the follicular adenoma/carcinoma class of tumor.
  • [MeSH-major] Carcinoma, Papillary, Follicular / classification. Carcinoma, Papillary, Follicular / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular. Humans. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / classification. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology. ras Proteins / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Sep 15;107(6):1255-64 [16900519.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):16-8 [11791591.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):861-5 [10955452.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):424-31 [8293410.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1181-5 [12599223.001]
  • [Cites] Head Neck Pathol. 2009 Mar;3(1):86-93 [20596997.001]
  • [Cites] Pathol Annu. 1983;18 Pt 1:221-53 [6877876.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):246-55 [3706611.001]
  • [Cites] Surgery. 1992 Dec;112(6):1130-6; discussion 1136-8 [1455315.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Mod Pathol. 2010 Sep;23(9):1191-200 [20526288.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1362-6 [14662540.001]
  • [Cites] Histopathology. 2004 Jan;44(1):35-9 [14717667.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):272-7 [10722027.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1512-20 [9850177.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):333-9 [8550774.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2616-25 [11352953.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1669-76 [16534796.001]
  • [Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):355-64 [15188460.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1997; author reply 1997-8 [14584085.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):505-24 [11169933.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):805-28 [3967175.001]
  • [Cites] Endocr Pract. 2001 Mar-Apr;7(2):79-84 [11421549.001]
  • (PMID = 21088998.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


20. Keskin A, Yilmazbas G, Yilmaz R, Ozyigit MO, Gumen A: Pathological abnormalities after long-term administration of medroxyprogesterone acetate in a queen. J Feline Med Surg; 2009 Jun;11(6):518-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, multiple abnormalities (bilateral ovarian cysts, cystic endometrial hyperplasia and pyometra (CEH-P), mammary adenoma, fibrosarcoma and cystic-papillary adenocarcinoma) identified in a queen continually administered medroxyprogesterone acetate (MPA) for 9 years are described.
  • Histopathologically, follicular ovarian cysts, CEH-P, and benign and neoplastic mammary lesions were identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Feline Med Surg. 2010 Sep;12(9):724 [20800213.001]
  • (PMID = 19058986.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


21. Sobota A, Pena M, Santi M, Ali Ahmed A: Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome. Int J Surg Pathol; 2007 Jul;15(3):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevoid basal cell carcinoma syndrome is an autosomal dominant multisystem disorder characterized by developmental anomalies and occurrence of multiple basal cell carcinomas and other tumors in early childhood.
  • In this article, the authors report a case of a 19-year-old African American male with nevoid basal cell carcinoma syndrome and a history of medulloblastoma at age 2, meningioma at age 14, thyroid follicular adenomas with papillary carcinoma at age 15, and 2 basal cell carcinomas at ages 16 and 18.


22. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol; 2008 Mar;158(3):375-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology.
  • This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms.
  • METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions.
  • CONCLUSION: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy (98%).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299472.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / PPAR gamma; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter
  •  go-up   go-down


23. Karger S, Engelhardt C, Eszlinger M, Tönjes A, Herrmann F, Müller P, Schmidt T, Weiss CL, Dralle H, Lippitzsch F, Tannapfel A, Führer D: Cytology and mRNA expression analysis of fine needle aspirates of thyroid nodules in an East German region with borderline iodine deficiency. Horm Metab Res; 2006 Oct;38(10):662-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration cytology (FNAC) is widely recommended as an important tool for pre-operative identification of malignancy in patients with nodular thyroid disease.
  • Two-hundred and forty-four consecutive FNACs were obtained over a period of 2 years (2002-2004) from euthyroid patients presenting for first evaluation of a solitary thyroid nodule.
  • In 55% of patients FNAC was performed after scintiscan detection of a cold or normal functioning thyroid nodule (CTN), while in the remainder FNAC was performed as a primary investigation.
  • FNAC outcomes were: 57.8% benign, 22.1% indeterminate, 2.5% suspicious for malignancy, 17.6% non-diagnostic.
  • However, subgroup analysis showed that FNAC with histologically confirmed follicular thyroid cancer and/or microfollicular adenoma exhibited significantly lower Tg mRNA expression despite high beta-actin levels.
  • In conclusion, quantitative mRNA analysis is feasible in FNA on a routine basis and provides a perspective for a molecular distinction of thyroid nodules, once specific marker genes have been defined for benign and malignant thyroid tumours respectively.

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075775.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Genetic Markers; 0 / RNA, Messenger; 9010-34-8 / Thyroglobulin; 9679TC07X4 / Iodine
  •  go-up   go-down


24. Rydlova M, Ludvikova M, Stankova I: Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun;152(1):53-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study.
  • METHODS: Forty eight thyroid lesions forming four diagnostic groups including adenomatous goiters (AS), follicular adenomas (FA), follicular (FC) and papillary carcinomas (PC) were examined using standard immunohistochemical methods.
  • Moreover, statistically significant differences between fused groups of benign (AS and FA) and malignant lesions (FC and PC) were found Fischer's exact test (p = 0.0001).
  • No significant differences in cytoplasmic expression of MMPs -2 and -7 and in vascular density assessed by using of both endothelial markers between benign lesions and malignant tumors were revealed.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 7 / analysis. Microvessels / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795075.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


25. Mihai R, Parker AJ, Roskell D, Sadler GP: One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma. Thyroid; 2009 Jan;19(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma.
  • Cytological criteria for benign (THY2) and malignant (THY5) aspirates are well established and reliable.
  • When cytology suggests a follicular neoplasm (THY3), only formal histological assessment can differentiate between benign and malignant lesions.
  • The objective of this study was to determine the factors predictive of malignancy in thyroid nodules when cytological assessment is restricted to euthyroid patients living in an area without endemic goiter who undergo routine diagnostic lobectomy once the FNA raises the suspicion of a follicular neoplasm.
  • Histology demonstrated thyroid carcinomas in 57 patients (31 follicular carcinomas, 11 Hurthle cell carcinomas, 11 papillary carcinomas, 1 medullary thyroid carcinoma, 1 poorly differentiated thyroid cancer, 1 lymphoma, and 1 metastatic renal carcinoma).
  • Benign tumors were found in 144 patients with follicular adenomas (n = 76), Hurthle cell adenomas (n = 33), multinodular goiter (n = 13), adenomatoid nodules (n = 15), colloid nodules (n = 4), and thyroiditis (n = 3).
  • CONCLUSION: One in four patients with cytological features of a follicular neoplasm has a thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cohort Studies. Diagnosis, Differential. Female. Humans. Incidence. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Risk Factors. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976164.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Satacińska-Los E, Kulig A, Włoch J: Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors. Pol J Pathol; 2005;56(1):27-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors.
  • In this study we analyzed, using immunohistochemical methods, the expression of cyclin D1 and Rb proteins in material from medical archives (12 cases of follicular thyroid carcinoma, 57 cases of follicular adenoma and 17 nodular goiter cases).
  • A positive nuclear reaction for cyclin D1 was observed in 83.3% (10/12) of the follicular carcinomas, in 96.5% (55/57) of the follicular adenomas and in 23.5% (4/17) of nodular goiters.
  • Overexpression of cyclin Dl (more than 50% of positively staining cells) was noted in 25% (3/12) of the follicular carcinomas and in 22.8% (13/57) of the follicular adenomas.
  • The number of carcinoma cases with cyclin D1 overexpression did not differ statistically in any significant way from the follicular adenoma group (p = 1.000).
  • A positive nuclear reaction for Rb protein was noted in 100% of the follicular carcinomas (12/12), in 96.5% of the follicular adenomas (55/57) and in 47.1% of the cases (8/17) of nodular goiter.
  • Rb protein overexpression (more than 50% of positively staining cells) was found in 83.3% (10/12) of the follicular carcinomas, in 68.4% (39/57) of the follicular adenomas and in 11.8% (2/17) of the nodular goiters.
  • The number of cases with Rb protein overexpression in the follicular carcinoma group did not differ significantly from that in the follicular adenoma group (p = 0.486).
  • In the follicular carcinoma group, that correlation was borderline (Rp = 0.437; p = 0.072) and, in the follicular adenoma group, it was statistically insignificant (Rs = 0.217; p = 0.105).
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Cyclin D1 / metabolism. Retinoblastoma Protein / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans


27. Heikkilä A, Siironen P, Hagström J, Heiskanen I, Sankila R, Louhimo J, Haglund C, Arola J: Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS; 2010 Nov;118(11):846-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy.
  • Thyroid follicular neoplasms are the most common tumors of the thyroid.
  • We found 356 follicular neoplasms treated between 1990 and 2006.
  • Among these tumor patients, adenomas were more common in women than in men (3.6:1), but carcinomas differed little with respect to gender (1.2:1).
  • All follicular carcinomas (n=39), atypical adenomas (n=6), and oxyphilic adenomas (n=15) were included in the study, as well as 30 consecutive conventional follicular adenomas.
  • Five tumors were reclassified as poorly differentiated follicular thyroid carcinomas, representing 13% of carcinomas in this unselected material.
  • Predictors of malignancy were high proliferation index (PI) by MIB-1 (p<0.001), large tumor size (p<0.001), and old age (p=0.006).
  • Oxyphilic tumor cells were more frequent in carcinomas than in adenomas; however, among carcinomas, they were non-prognostic.
  • Probability for malignancy is thus greater in a male patient with a large oxyphilic follicular neoplasm.
  • The PI requires evaluation in all follicular thyroid carcinomas to identify poorly differentiated tumors with worse prognosis.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclin D1 / biosynthesis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Tumor Suppressor Protein p53 / biosynthesis. Ubiquitin-Protein Ligases / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 20955457.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


28. Wasim T, Majrroh A, Siddiq S: Comparison of clinical presentation of benign and malignant ovarian tumours. J Pak Med Assoc; 2009 Jan;59(1):18-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clinical presentation of benign and malignant ovarian tumours.
  • OBJECTIVE: To compare clinical presentation of benign and malignant ovarian tumours and to enlist and identify symptoms that could lead to early diagnosis of ovarian carcinoma METHODS: It was a consecutive case series study.
  • RESULTS: The study included 110 patients, of whom 80 (72%) had benign and the rest malignant disease.
  • Mean age of patients with malignancy was 49.07+/-18.5 years and for benign 36.95+/-8.2 years (p= 0.0001).
  • Eleven patients with benign tumours were asymptomatic, while 66% had abdominal pain.
  • Histopathology of benign tumours revealed follicular/luteal cyst in 32% cases while serous cyst adenoma in 23%.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213371.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


29. Xu MR, Chen Y, Zhou SR, Chi MM, Chen SL, Liu LY: [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2009 May;31(5):356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the mRNA expressions of RASSF1A, Galectin-3 and TPO in papillary thyroid carcinoma and some other thyroid benign lesions, and evaluate their diagnostic significance.
  • METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of RASSF1A, galectin-3 and TPO in the samples from 73 cases, including 23 cases with papillary thyroid cancer, 16 with nodular goiter, 29 with thyroid adenoma and 5 with Hashimoto's disease.
  • RESULTS: A statistically significant difference in the mRNA expression of RASSF1A, Galectin-3 and TPO was observed between papillary thyroid carcinoma and follicular benign lesions (P<0.05).
  • However, there was no significant difference among various kinds of benign lesions (P>0.05).
  • A negative correlation of the expression of RASSF1A and Galectin-3 mRNA was found between thyroid benign lesions and malignant ones (P = 0.000).
  • While the mRNA expression of RASSF1A and TPO was positively correlated between benign and malignant lesions (P = 0.028).
  • Therefore, the products of these three genes may be closely related to the development of thyroid papillary carcinoma, and may be used as useful markers in differential diagnosis of papillary thyroid carcinoma from the benign lesions.
  • [MeSH-major] Autoantigens / metabolism. Carcinoma, Papillary / metabolism. Galectin 3 / metabolism. Iodide Peroxidase / metabolism. Iron-Binding Proteins / metabolism. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Goiter, Nodular / genetics. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / genetics. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Male. Middle Aged. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799084.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Iron-Binding Proteins; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


30. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI: Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol; 2009 Nov;16(11):3140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were subdivided into two groups based on final pathology results: patients with DTC(n=61) and those with benign disease (BD) (n=54).
  • RESULTS: Of 115 operated patients with solitary thyroid nodules, 53% (61/115) had DTC [papillary, 59%; follicular variant/papillary, 34%; Hürthle cell, 5%; and follicular, 2%] and 47% (54/115) had BD [hyperplastic, 56%; follicular adenoma, 31%; lymphocytic thyroiditis, 7%; and Hürthle cell adenoma, 6%].
  • These SUS characteristics may have additional clinical value in predicting DTC in patients with solitary thyroid nodules.
  • [MeSH-major] Carcinoma, Papillary, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S301 [20839063.001]
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):292 [20490696.001]
  • (PMID = 19655201.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Steff M, Bourillon A, Frebourg T, Balderi X, Descamps V, Joly P, Piette F, Crestani B, Grandchamp B, Soufir N: [Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]. Ann Dermatol Venereol; 2010 Mar;137(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Birt-Hogg-Dubé syndrome (BHDS) is an autosomal-dominantly inherited genodermatosis that predisposes to the development of benign hair follicle tumours, lung cysts, kidney tumours, and possibly colonic cancers, due to mutations in the FLCN gene.
  • The first proband showed fibrofolliculomas (FF), a history of pneumothorax and colonic adenoma.
  • This case emphasises the vital importance of presymptomatic diagnosis for each member of a BHDS family by means of a cancer genetics consultation, followed by a CT scan of the chest and abdomen, colonoscopy and annual kidney imaging.
  • [MeSH-major] Frameshift Mutation. Hair Follicle / pathology. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Colonic Neoplasms / genetics. Emphysema / genetics. Female. Hair Diseases / genetics. Humans. Male. Middle Aged. Pedigree. Phenotype. Pneumothorax / genetics. Sequence Analysis, Protein

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Masson SAS.
  • (PMID = 20227563.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


32. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer; 2009 Aug 15;125(4):894-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
  • The identification of high-risk patients with thyroid cancer and the preoperative differentiation between follicular adenoma and carcinoma remain clinically challenging.
  • Tumor/normal tissue was collected from 69 prospectively followed patients with thyroid carcinomas (papillary, medullary, follicular and anaplastic, PTC, MTC, FTC and ATC) or follicular adenomas.
  • Carcinomas except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.
  • MMP-1 and MMP-9 were significantly higher in follicular carcinomas than in adenomas.
  • Poor survival in differentiated tumors was associated in trend (p = 0.07); poor survival of all patients (p = 0.043) and especially of patients with carcinomas of follicular origin (including ATC), but not medullary carcinomas, were significantly associated with high u-PAR-protein (p = 0.015).
  • This is the first study to suggest MMP-1/-9 as significant differentiation markers between follicular adenoma and follicular carcinoma.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Blotting, Western. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480010.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


33. Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L, Farag A, Zanation AM: Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg; 2008 Jun;134(6):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
  • OBJECTIVES: To use immunohistochemical (IHC) evaluation of proteins encoded by genes that were differentially expressed in follicular thyroid adenomas (FAs) vs follicular thyroid carcinomas (FTCs) to distinguish benign vs malignant follicular thyroid lesions.
  • Multiple gene microarray studies suggest that benign and malignant follicular thyroid neoplasms have different gene expression profiles.
  • DESIGN: Immunohistochemical analysis of thyroid neoplasms, including FA (n = 62), FTC (n = 62), and follicular variant of papillary thyroid carcinoma (n = 58), using tissue microarrays.
  • We analyzed data for quantitative differences in IHC intensity and the percentage of positive cells between FAs and combined follicular carcinomas.
  • PATIENTS: Adults with known follicular and papillary thyroid lesions that were surgically resected during the past 15 years.
  • MAIN OUTCOME MEASURES: Sensitivity and specificity of individual and combined antibodies for detecting benign from malignant lesions.
  • Future studies should focus on clinical translation of these molecular differences for the diagnosis of follicular thyroid neoplasms.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Thyroid Neoplasms / diagnosis


34. Huber GF, Dziegielewski P, Matthews TW, Warshawski SJ, Kmet LM, Faris P, Khalil M, Dort JC: Intraoperative frozen-section analysis for thyroid nodules: a step toward clarity or confusion? Arch Otolaryngol Head Neck Surg; 2007 Sep;133(9):874-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case of malignant FNAC findings, the FS result did not influence treatment decisions; in case of a malignant FS result on the background of a benign, indeterminate, or nondiagnostic FNAC finding, the FS result influenced treatment decisions in 88% of cases.
  • CONCLUSIONS: Intraoperative FS did not give additional information in cases where a malignant neoplasm was predicted by the FNAC finding.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle. Frozen Sections. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Decision Support Techniques. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Thyroid Diseases / pathology. Thyroid Diseases / surgery. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875853.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Di Tommaso L, Tresoldi D, Navligu CI, Destro A, Comi P, Morbiducci U, Roncalli M, Rizzo G: A 3-D study of capsular invasion in follicular thyroid tumors. A novel approach to an old dilemma. Pathologica; 2010 Jun;102(3):93-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 3-D study of capsular invasion in follicular thyroid tumors. A novel approach to an old dilemma.
  • OBJECTIVE: The diagnosis of follicular tumors of the thyroid mainly rests on the examination of peri-lesional capsule.
  • Lesions with an intact shell are labeled as adenoma, those with capsular invasion are considered carcinoma and those with doubtful aspects are regarded as tumors of uncertain malignant potential.
  • METHOD: Two follicular carcinoma (FC) and one follicular tumour of uncertain malignant potential (FT-UMP) were considered.
  • In one FC the hole was entirely engaged by a tumor mass.
  • CONCLUSIONS: Our approach allows a better spatial reconstruction of the exact point of capsular interruption; the results obtained suggest that capsular invasion can be due either by abruptly interruption of the shell or by a protrusion along the path of a small feeding vessel.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Imaging, Three-Dimensional / methods. Thyroid Neoplasms / pathology. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21171511.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B: PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab; 2005 Jan;90(1):463-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.
  • The PAX8/PPARgamma (PPFP) fusion-oncogene is moderately specific for follicular thyroid carcinomas (FTC).
  • We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hurthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARgamma immunohistochemistry (as a surrogate of PAX8/PPARgamma expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section.
  • PPARgamma staining was associated with favorable prognostic indicators (female gender, better tumor differentiation, and lesser risk of metastases).PPARgamma staining may be helpful in the differential diagnosis of FA, FTC, and HCC, particularly when diagnostic sensitivity of histomorphology is reduced (e.g. during intraoperative frozen section).
  • [MeSH-major] Adenoma / chemistry. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Oncogenes. PPAR gamma / analysis. PPAR gamma / genetics. Recombinant Fusion Proteins / genetics. Thyroid Neoplasms / chemistry. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15483076.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA80117
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Recombinant Fusion Proteins; 0 / Trans-Activators
  •  go-up   go-down


37. Sekizawa N, Hayakawa E, Tsuchiya K, Yoshimoto T, Akashi T, Fujii T, Yamada S, Hirata Y: Acromegaly associated with multiple tumors. Intern Med; 2009;48(15):1273-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed with acromegaly due to his characteristic clinical features, endocrine data, and the presence of pituitary tumor.
  • He was found to have colon cancer and follicular thyroid tumor.
  • Pathological examination of the pituitary tumor after transsphenoidal surgery was compatible with growth hormone (GH)-secreting pituitary adenoma.
  • We also detected the transcripts and/or immunoreactivity of GH/insulin-like growth factor I components in the tumor specimen.
  • This is a rare case of acromegaly associated with multiple tumors, including RCC, colon cancer and thyroid tumor.

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652429.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Receptors, Somatotropin; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


38. Serra A, Bolasco P, Satta L, Nicolosi A, Uccheddu A, Piga M: Role of SPECT/CT in the preoperative assessment of hyperparathyroid patients. Radiol Med; 2006 Oct;111(7):999-1008
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Our purpose was to assess the clinical value and additional benefit of fusion single-photon computed tomography (SPECT) and computed tomography (CT) images in locating the parathyroids in a selected group of patients affected by primary (PHP) and secondary hyperparathyroidism (SHP).
  • Sixteen of these foci of increased uptake were hyperplastic parathyroid glands, six were adenomas, one was a parathyroid carcinoma and one was a thyroid follicular carcinoma.
  • CONCLUSIONS: We believe 99mTc-sestamibi SPECT/CT to be a more reliable presurgical method to study a patient subgroup affected by PHP or SHP in whom conventional US and other scintigraphic methods have failed for intrinsic reasons due to the concomitant presence of multinodular goitre or ectopic parathyroid gland.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021682.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


39. Wani S, Hao Z: Atypical cystic adenoma of the parathyroid gland: case report and review of literature. Endocr Pract; 2005 Nov-Dec;11(6):389-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cystic adenoma of the parathyroid gland: case report and review of literature.
  • OBJECTIVE: To describe the clinical course of a patient with atypical cystic parathyroid adenoma manifesting as hypercalcemic parathyroid crisis.
  • METHODS: We present a case report and review the relevant literature on parathyroid cysts and atypical cystic parathyroid adenomas.
  • She underwent surgical exploration of the neck, total thyroidectomy for multinodular disease of the thyroid, and subtotal parathyroidectomy.
  • The final pathologic diagnosis was an atypical cystic parathyroid adenoma.
  • CONCLUSION: Parathyroid cysts are uncommon and should be considered in the differential diagnosis of a neck mass.
  • Atypical cystic parathyroid adenomas are rare and have an unpredictable clinical course.
  • They exhibit some features of carcinoma but lack the indisputable evidence of malignant disease, such as angioinvasion or metastatic involvement.
  • [MeSH-major] Follicular Cyst / diagnosis. Parathyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638726.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  • [Number-of-references] 21
  •  go-up   go-down


40. Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J: Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid; 2006 Nov;16(11):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin.
  • Recently, we have been able to describe the involvement of a novel gene called THADA in benign thyroid lesions with 2p21 rearrangements.
  • The latter occurs in follicular thyroid carcinomas with a t(2;3)(q13;p25).
  • Here we present molecular-cytogenetic and cytogenetic investigations on a follicular thyroid adenoma with a t(2;20;3)(p21;q11.2; p25).
  • Our findings suggest that the close surrounding of PPAR(gamma) is a breakpoint hot spot region, leading to recurrent alterations of this gene in thyroid tumors of follicular origin including carcinomas as well as adenomas with or without involvement of PAX8.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Breakage. Neoplasm Proteins / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123335.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / THADA protein, human
  •  go-up   go-down


41. Takano T, Higashiyama T, Uruno T, Yamada H, Yoshida H, Miyauchi A: Preparation of thyroid tumor cells in aspiration biopsies for aspiration biopsy nucleic acid diagnosis. Head Neck; 2008 Aug;30(8):983-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation of thyroid tumor cells in aspiration biopsies for aspiration biopsy nucleic acid diagnosis.
  • BACKGROUND: The relative expression level of trefoil factor 3 (TFF3) mRNA to galectin-3 (LGALS3) mRNA (T/G ratio) is a useful marker to distinguish thyroid follicular carcinomas from adenomas.
  • METHODS: We tested 2 methods of selecting thyroid tumor cells and removing blood cells from the aspirates.
  • [MeSH-major] Galectin 3 / metabolism. Peptides / metabolism. RNA, Messenger / metabolism. Thyroid Gland / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Antigens, CD45 / metabolism. Biomarkers, Tumor / immunology. Biopsy, Fine-Needle. Cell Separation. Filtration / instrumentation. Humans. Immunomagnetic Separation. Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302262.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Peptides; 0 / RNA, Messenger; 0 / TFF3 protein, human; 0 / human epithelial antigen-125; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


42. Lozano-Gómez MJ, Sánchez-Blanco JM, Vázquez-Morón M, Parra-Membrives P, Torres-Arcos C, Jurado-Jiménez R, Gómez-Rubio D, Recio-Moyano G: [Hemithyroidectomy in a unilateral goiter: a valid therapeutic option. Review of the contralateral hemithyroid ten years after treatment]. Cir Esp; 2006 Jul;80(1):23-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Nodular goiter (NG) is frequent among the general population and is considered a diffuse disease.
  • The aim of the present study was to evaluate the remaining thyroid in patients with NG compared with those with follicular adenoma who underwent hemithyroidectomy.
  • Patients with follicular adenoma (with normal contralateral ultrasonography) who underwent hemithyroidectomy during the same period were selected to form the control group (CG).
  • None of the patients underwent reintervention for nodular disease.
  • [MeSH-major] Goiter, Nodular / surgery. Thyroid Gland / pathology. Thyroidectomy / methods

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796949.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


43. Wozniak A, Wiench M, Olejniczak A, Wloch J, Lachinski A, Lange D, Olczyk T, Jarzab B, Limon J: Loss of heterozygosity in 73 human thyroid tumors. Neuro Endocrinol Lett; 2005 Oct;26(5):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of the study was to establish the LOH frequency of selected polymorphic markers in different histological types of thyroid tumors: 18 colloid goiters (CG), five follicular adenomas (FA), nine follicular carcinomas (FTC), 40 papillary carcinomas (PTC), and one anaplastic carcinoma (ATC).
  • CONCLUSIONS: We conclude that papillary thyroid cancers, particularly those diagnosed in patients older than 45 years of age, do exhibit LOH at least with the same frequency as follicular cancers.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264407.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


44. Rothhut B, Ghoneim C, Antonicelli F, Soula-Rothhut M: Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase. Biochimie; 2007 May;89(5):613-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase.
  • In order to further advance our knowledge of the role epidermal growth factor (EGF) plays in thyroid carcinoma, we investigated its effect on the regulation of matrix metalloproteinase-9 (MMP-9), a key enzyme that plays an important role in tumor invasion and angiogenesis.
  • The expression of MMP-9 in EGF-treated and untreated human follicular thyroid carcinoma cells (FTC-133) was evaluated using reverse transcription-PCR, Western blot and gelatin zymography.
  • In the present study, we demonstrate that EGF treatment up-regulated MMP-9 expression in human follicular thyroid carcinoma cells.
  • Our studies highlight the role FAK plays in promoting cell invasion through the activation of distinct signaling pathways induced by EGF with protein MMP-9 transcription and secretion in follicular thyroid carcinoma cells.
  • [MeSH-major] Adenoma / pathology. Epidermal Growth Factor / pharmacology. Focal Adhesion Protein-Tyrosine Kinases / physiology. Gene Expression Regulation, Neoplastic / drug effects. Matrix Metalloproteinase 9 / genetics. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Binding Sites. Cell Line, Tumor. Focal Adhesion Kinase 1 / physiology. Humans. Neoplasm Proteins / physiology. Promoter Regions, Genetic. Signal Transduction. Transcription Factor AP-1

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397984.001).
  • [ISSN] 0300-9084
  • [Journal-full-title] Biochimie
  • [ISO-abbreviation] Biochimie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Transcription Factor AP-1; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK2 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


45. Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol; 2006;17(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial immunohistochemical studies claimed that TPO expression, detected by the monoclonal antibody mAb 47, may be a potentially important diagnostic tool in differentiating malignant from benign lesions.
  • TPO expression was investigated using newly available mAb 47 and staining of less than 80% of the follicular cells/specimen as the threshold indicating a malignant lesion.
  • We found that TPO had a sensitivity of 89.9% for cancer and a specificity of 64.4% for nonmalignant lesions, showing that it does not give a sufficient degree of diagnostic certainty that the lesion is benign.
  • In addition, the variability in the degree of TPO expression found within and between follicular carcinomas, and the significant number of benign adenomas having similar immunostaining patterns, assured us that TPO immunostaining is not sufficiently discriminatory in the differential diagnosis of thyroid cancer versus benign lesions.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Immunoenzyme Techniques. Retrospective Studies. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cesk Patol. 2004 Jan;40(1):18-21 [15035056.001]
  • [Cites] Endocr Pathol. 1998 Winter;9(1):333-338 [12114781.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Pathol. 1996 May;179(1):89-94 [8691351.001]
  • [Cites] Cancer Detect Prev. 1996;20(4):285-93 [8818388.001]
  • [Cites] Endocr J. 1996 Feb;43(1):53-60 [8732452.001]
  • [Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]
  • [Cites] J Clin Endocrinol Metab. 1978 May;46(5):791-9 [262767.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 14;174(3):1148-53 [1996981.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3793-800 [12454013.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Eur J Endocrinol. 1994 Nov;131(5):474-9 [7952158.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2478-82 [7852309.001]
  • [Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):223-228 [12114702.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):425-30 [3618217.001]
  • [Cites] Endocrinol Jpn. 1981 Aug;28(4):381-9 [6305643.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1329-34 [8067701.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):271-6 [2393055.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]
  • [Cites] Exp Clin Endocrinol. 1992;100(1-2):51-6 [1281780.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2572-9 [11327880.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9 [10931096.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Nov;45(5):1089-96 [925133.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):867-71 [8157713.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):24-32 [8651700.001]
  • [Cites] Thyroid. 1998 Sep;8(9):745-9 [9777743.001]
  • [Cites] Thyroid. 2000 Feb;10(2):109-15 [10718546.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • (PMID = 16760580.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


46. Kaspareit J, Friderichs-Gromoll S, Buse E, Habermann G: Spontaneous neoplasms observed in cynomolgus monkeys (Macaca fascicularis) during a 15-year period. Exp Toxicol Pathol; 2007 Nov;59(3-4):163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The great majority of neoplasms was benign (23 benign neoplasms versus 10 malignant tumors).
  • The age of tumor-bearing animals ranged between 2 years 2 months and 13 years 9 months.
  • Most of the tumors (22) in the cynomolgus monkeys were seen in endocrine organs (adrenal cortical adenoma, adrenal hemangioma, C-cell carcinoma, follicular adenoma), respiratory system (nasal cavity adenoma, pulmonary squamous cell carcinoma, bronchio-alveolar carcinoma, bronchiolar papilloma, chondromatous hamartoma) and female genital system (uterine polyp, uterine adenoma, uterine leiomyoma and teratoma of the ovary).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869495.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Thamboo TP, Tan LH, Tan SY: Expression of Bcl-x in normal skin and benign cutaneous adnexal tumors. J Cutan Pathol; 2006 Jan;33(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-x in normal skin and benign cutaneous adnexal tumors.
  • Little is known about the expression of Bcl-x in cutaneous adnexal structures and benign cutaneous adnexal tumors.
  • METHODS: Tissues from 31 cases of benign cutaneous adnexal tumors (five trichofolliculomas, five trichoepitheliomas, two sebaceous adenomas, five apocrine hidradenomas, five eccrine poromas, five eccrine spiradenomas, and four syringomas) were immunostained for Bcl-x.
  • RESULTS: Strong staining for Bcl-x was seen in cells of the epidermal granular layer and inner root sheath of hair follicles.
  • Sebaceous gland cells showed strong staining.
  • Apocrine gland cells showed weak to moderate staining.
  • No staining was seen in eccrine gland cells.
  • In sebaceous adenomas, the sebaceous cells showed strong staining while the basaloid cells were negative.
  • This pattern is recapitulated in the corresponding benign cutaneous adnexal tumors.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Epidermis / metabolism. Epidermis / pathology. Humans. Immunoenzyme Techniques. Sebaceous Glands / metabolism. Sebaceous Glands / pathology. Sweat Glands / metabolism. Sweat Glands / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441408.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / bcl-X Protein
  •  go-up   go-down


48. Gupta N, Kakar AK, Chowdhury V, Gulati P, Shankar LR, Vindal A: Magnetic resonance spectroscopy as a diagnostic modality for carcinoma thyroid. Eur J Radiol; 2007 Dec;64(3):414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenoma / diagnosis. Adenoma / pathology. Adolescent. Adult. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Child. Choline / analysis. Cysts / diagnosis. Cysts / pathology. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / pathology. Thyroiditis, Autoimmune / diagnosis. Thyroiditis, Autoimmune / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462842.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] N91BDP6H0X / Choline
  •  go-up   go-down


49. Culp SJ, Mellick PW, Trotter RW, Greenlees KJ, Kodell RL, Beland FA: Carcinogenicity of malachite green chloride and leucomalachite green in B6C3F1 mice and F344 rats. Food Chem Toxicol; 2006 Aug;44(8):1204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female rats exposed to malachite green chloride had increased incidences of thyroid gland follicular cell adenoma or carcinoma and hepatocellular adenoma, and a dose-related increasing trend in mammary gland carcinoma.
  • In male rats fed leucomalachite green there was a decreasing trend in pituitary gland adenoma and an increasing trend in interstitial cell adenoma of the testis.
  • Female mice fed leucomalachite green had a dose-related increasing trend in the incidence of hepatocellular adenoma or carcinoma, with the incidence being significant in the highest dose group.

  • Hazardous Substances Data Bank. Leucomalachite green .
  • Hazardous Substances Data Bank. MALACHITE GREEN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554117.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Fungicides, Industrial; 0 / Rosaniline Dyes; 12058M7ORO / malachite green; 8U61G37Z20 / leucomalachite green
  •  go-up   go-down


50. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M: Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol; 2005 Feb;27(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation.
  • Brooke-Spiegler syndrome is an autosomal dominantly inherited disease with predisposition to cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.
  • The histopathological survey revealed a plethora of benign adnexal neoplasms showing apocrine, follicular, and sebaceous differentiation occurring independently and conjointly.
  • By far the most common composite tumor was spiradenocylindroma.
  • [MeSH-minor] Adenoma, Sweat Gland / metabolism. Adenoma, Sweat Gland / pathology. Adenoma, Sweat Gland / surgery. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Hair Diseases / metabolism. Hair Diseases / pathology. Hair Diseases / surgery. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunoenzyme Techniques. Male. Sebaceous Glands / metabolism. Sebaceous Glands / pathology. Syndrome

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677973.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, Lindenthal S, Ettore F, Darcourt J, Pourcher T: Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol; 2009 Feb;160(2):215-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
  • OBJECTIVE: The active transport of iodide into thyroid cells is mediated by the Na(+)/I(-) symporter (NIS) located in the basolateral membrane.
  • Strong intracellular staining with anti-NIS antibodies has been reported in thyroid and breast cancers.
  • Our initial objective was to screen tumour samples for intracellular NIS staining and then to study the mechanisms underlying the altered subcellular localization of the transporters.
  • METHODS: Immunostaining using three different anti-NIS antibodies was performed on paraffin-embedded tissue sections from 93 thyroid or breast cancers.
  • Western blot experiments were carried out to determine the amount of NIS protein in 20 samples.
  • RESULTS: Using three different anti-NIS antibodies, we observed intracellular staining in a majority of thyroid tumour samples.
  • Control immunohistochemistry and western blot experiments indicated that this intracellular staining was due to non-specific binding of the antibodies.
  • In breast tumours, very weak intracellular staining was observed in some samples.
  • Western blot experiments suggest that this labelling is also non-specific.
  • CONCLUSIONS: Our results strongly indicate that the NIS protein level is low in thyroid and breast cancers and that the intracellular staining obtained with anti-NIS antibodies corresponds to a non-specific signal.
  • Accordingly, to increase the efficiency of radiotherapy for thyroid cancers and to enable the use of radioiodine in the diagnosis and therapy of breast tumours, improving NIS targeting to the plasma membrane will not be sufficient.
  • Instead, increasing the expression level of NIS should remain the major goal of this field.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029227.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodides; 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


52. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC, Kulcsar MA, Kimura ET: Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although TGF-beta and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins.
  • MATERIALS AND METHODS: The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry.
  • RESULTS: The expression of pSMAD2/3, SMAD4 and SMAD7 was observed in both benign and malignant thyroid tumors.
  • Although pSMAD2/3, SMAD4 and SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions.
  • CONCLUSIONS: The finding of SMADs expression in thyroid cells and the presence of pSMAD2/3 and SMAD4 proteins in the nucleus of tumor cells indicates propagation of TGF-beta/activin signaling.
  • [MeSH-minor] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Goiter, Nodular / metabolism. Humans. Signal Transduction / physiology. Smad2 Protein / analysis. Smad3 Protein / analysis. Smad4 Protein / analysis. Smad7 Protein / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625653.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD4 protein, human; 0 / SMAD7 protein, human; 0 / Smad Proteins, Receptor-Regulated; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Smad7 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins
  •  go-up   go-down


53. Wang SL, Li SH, Chen WT, Chai CY: Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma. APMIS; 2007 Aug;115(8):906-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical pathologic criteria for nuclear features of papillary thyroid carcinoma are subjective and sometimes cannot distinguish carcinoma from adenomatous goiter and follicular neoplasms.
  • Controls included 36 follicular adenomas, 36 follicular carcinomas, and 20 adenomatous goiters with papillary hyperplasia.
  • Cytoplasmic D2-40 immunoreactivity was present in 60 of 72 papillary carcinomas, 2 cases of follicular adenoma and 2 cases of follicular carcinoma, whereas no adenomatous goiter or normal thyroid glands contained positive epithelial cells.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696946.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


54. Gingalewski CA, Newman KD: Seminars: controversies in the management of pediatric thyroid malignancy. J Surg Oncol; 2006 Dec 15;94(8):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It often presents at advanced stages, yet behaves in a benign manner, when compared to its adult counterpart.
  • The best operative and adjuvant strategy for these children can only be determined when a better understanding of the tumor cell biology and genetics of this cancer is known.
  • [MeSH-minor] Adenoma / genetics. Adult. Carcinoma, Papillary. Carcinoma, Papillary, Follicular / secondary. Carcinoma, Papillary, Follicular / surgery. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Hypoparathyroidism / etiology. Lymph Node Excision. Monitoring, Intraoperative. Mutation. Parathyroid Hormone / blood. Postoperative Complications. Proto-Oncogene Proteins c-ret / genetics. Recurrent Laryngeal Nerve Injuries. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131405.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Parathyroid Hormone; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 15
  •  go-up   go-down


55. Snabboon T, Plengpanich W, Saengpanich S, Sirisalipoch S, Keelawat S, Sunthornyothin S, Khovidhunkit W, Suwanwalaikorn S, Sridama V, Shotelersuk V: Two common and three novel PDS mutations in Thai patients with Pendred syndrome. J Endocrinol Invest; 2007 Dec;30(11):907-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pendred syndrome is an autosomal recessive disorder characterized by congenital sensorineural deafness, goiter, and impaired iodide organification.
  • Follicular thyroid carcinoma and Hürthle cell adenoma were found in affected members of a family, raising the possibility of an increased risk of thyroid carcinoma in Pendred syndrome patients.
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Adult. Alleles. Female. Humans. Iodides / metabolism. Male. Middle Aged. Pedigree. Risk Factors. Syndrome. Thailand. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Pendred syndrome.
  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4221-6 [11274445.001]
  • [Cites] J Med Genet. 2003 Apr;40(4):242-8 [12676893.001]
  • [Cites] Laryngoscope. 2006 Nov;116(11):2027-36 [17075407.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4162-6 [9814507.001]
  • [Cites] Acta Otolaryngol. 2000 Mar;120(2):137-41 [11603758.001]
  • [Cites] Hum Genet. 1999 Feb;104(2):188-92 [10190331.001]
  • [Cites] Clin Endocrinol Metab. 1981 Jul;10(2):317-35 [7285382.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2028-33 [10843192.001]
  • [Cites] Hum Mol Genet. 1998 Jul;7(7):1099-104 [9618166.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2678-81 [16684826.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):411-22 [9398842.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Aug;263(8):699-704 [16703388.001]
  • [Cites] Hum Mutat. 1998;11(1):1-3 [9450896.001]
  • [Cites] Hum Mutat. 2001 May;17(5):403-11 [11317356.001]
  • [Cites] J Med Genet. 1999 Jun;36(6):475-7 [10874637.001]
  • [Cites] Thyroid. 2001 Oct;11(10):981-8 [11716048.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F356-64 [11208611.001]
  • [Cites] Endocrinology. 2000 Feb;141(2):839-45 [10650967.001]
  • [Cites] Clin Radiol. 1998 Apr;53(4):268-73 [9585042.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):938 [11836344.001]
  • [Cites] Am J Med Genet A. 2004 Jan 1;124A(1):1-9 [14679580.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):13004-10 [14715652.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3356-61 [12107249.001]
  • [Cites] Hum Mol Genet. 1998 Jul;7(7):1105-12 [9618167.001]
  • [Cites] Eur J Hum Genet. 2006 Jun;14 (6):773-9 [16570074.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4367-72 [11095481.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9727-32 [10449762.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1709-15 [10861298.001]
  • [Cites] Eur J Hum Genet. 2003 Dec;11(12):916-22 [14508505.001]
  • [Cites] J Med Genet. 1999 Aug;36(8):595-8 [10465108.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2191-3 [2004339.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):77-8 [12112665.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3907-11 [11502831.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Jan;284(1):E25-8 [12388138.001]
  • (PMID = 18250610.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iodides; 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human
  •  go-up   go-down


56. Coiré CI, Horvath E, Smyth HS, Kovacs K: Rapidly recurring folliculostellate cell tumor of the adenohypophysis with the morphology of a spindle cell oncocytoma: case report with electron microscopic studies. Clin Neuropathol; 2009 Jul-Aug;28(4):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly recurring folliculostellate cell tumor of the adenohypophysis with the morphology of a spindle cell oncocytoma: case report with electron microscopic studies.
  • We report a rapidly recurring folliculostellate cell tumor of the adenohypophysis in a 63-year-old woman.
  • Morphologically the tumor had the typical appearance of a spindle cell oncocytoma of the adenohypophysis.
  • In our case, the ultrastructural features were significantly different from those so far described in SCO, in that tumor cells formed a network of structures indistinguishable from pituitary follicles.
  • In addition, a minority of tumor cells exhibited endocrine differentiation.
  • [MeSH-major] Adenoma, Oxyphilic / ultrastructure. Pituitary Neoplasms / ultrastructure
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Middle Aged

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642510.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Pagedar NA, Chen DH, Wasman JK, Savvides P, Schluchter MD, Wilhelm SM, Lavertu P: Molecular classification of thyroid nodules by cytology. Laryngoscope; 2008 Apr;118(4):692-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have characterized differences in gene expression between benign and malignant conditions, most often using whole tissue.
  • RT-PCR revealed satisfactory RNA recovery in all other specimens. qPCR showed significant over-expression of fibronectin in the papillary carcinomas compared with the goiters (P = .0013), follicular adenomas (P = .0014), and follicular carcinomas (P = .0001).
  • Differences in both fibronectin and MUC1 expression between the follicular carcinomas and the follicular adenomas were also significant (P = .025 and .045, respectively).
  • Both fibronectin and MUC1 were differentially expressed in follicular adenomas and follicular carcinomas, and fibronectin expression differed in papillary carcinomas compared with the other lesions.
  • These results may form the basis of a clinical predictor for lesions with indeterminate or suspicious cytology.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Antigens, CD3 / analysis. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / pathology. Cell Adhesion Molecules / analysis. Feasibility Studies. Fibronectins / analysis. Galectin 3 / analysis. Gene Expression Regulation, Neoplastic / genetics. Goiter / pathology. Humans. Molecular Biology. Mucin-1 / analysis. Polymerase Chain Reaction. Prospective Studies. Protein-Tyrosine Kinases / analysis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-met. Receptors, Growth Factor / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094649.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Fibronectins; 0 / Galectin 3; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / tumor-associated antigen GA733; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


58. Hoshi S, Hoshi N, Okamoto M, Paiz J, Kusakabe T, Ward JM, Kimura S: Role of NKX2-1 in N-bis(2-hydroxypropyl)-nitrosamine-induced thyroid adenoma in mice. Carcinogenesis; 2009 Sep;30(9):1614-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of NKX2-1 in N-bis(2-hydroxypropyl)-nitrosamine-induced thyroid adenoma in mice.
  • A significantly higher incidence of adenomas was obtained in Nkx2-1-thyroid-conditional hypomorphic mice as compared with the other two groups of mice only when they were treated with DHPN + SDM, but not amitrole.
  • A bromodeoxyuridine incorporation study revealed that thyroids of the Nkx2-1-thyroid-conditional hypomorphic mice had >2-fold higher constitutive cell proliferation rate than the other two groups of mice, suggesting that this may be at least partially responsible for the increased incidence of adenoma in this mouse line after genotoxic carcinogen exposure.
  • Thus, NKX2-1 may function to control the proliferation of thyroid follicular cells following damage by a genotoxic carcinogen.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMITROLE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):368-74 [10804283.001]
  • [Cites] J Diabetes Complications. 2010 May-Jun;24(3):163-7 [19217320.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;66:307-56 [11051768.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):899-905 [11011117.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):613-8 [11285197.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Toxicol Pathol. 2004 Mar-Apr;32(2):229-36 [15200161.001]
  • [Cites] Genesis. 2004 Jul;39(3):212-6 [15282748.001]
  • [Cites] Endocr Rev. 2004 Oct;25(5):722-46 [15466939.001]
  • [Cites] Gan. 1978 Aug;69(4):573-7 [710806.001]
  • [Cites] Carcinogenesis. 1982;3(10):1187-90 [7172417.001]
  • [Cites] Toxicol Appl Pharmacol. 1983 Jun 30;69(2):161-9 [6868082.001]
  • [Cites] Gan. 1984 Jun;75(6):502-7 [6468838.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):877-83 [3940650.001]
  • [Cites] Toxicol Pathol. 1989;17(2):294-306 [2675280.001]
  • [Cites] EMBO J. 1989 Sep;8(9):2537-42 [2583123.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6216-24 [2174102.001]
  • [Cites] Mol Cell Biol. 1992 Feb;12(2):576-88 [1732732.001]
  • [Cites] Mol Endocrinol. 1993 Dec;7(12):1589-95 [8145764.001]
  • [Cites] Mol Endocrinol. 1994 Aug;8(8):1049-69 [7997232.001]
  • [Cites] Cancer Lett. 1995 Sep 25;96(2):155-61 [7585451.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Cancer Lett. 1996 Feb 27;100(1-2):55-62 [8620454.001]
  • [Cites] Carcinogenesis. 1997 Feb;18(2):265-9 [9054617.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1747-55 [9328356.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106(8):437-45 [9681970.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1625-8 [9794240.001]
  • [Cites] IARC Sci Publ. 1999;(147):45-59 [10457909.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] Exp Toxicol Pathol. 2005 Nov;57(2):91-103 [16325520.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):25-31 [16367917.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1796-809 [16601074.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):959-66 [17283127.001]
  • [Cites] Neuro Endocrinol Lett. 2007 Apr;28(2):77-105 [17435680.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4251-8 [17584961.001]
  • [Cites] PLoS One. 2007;2(10):e1087 [17971852.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):460-4 [19198613.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • (PMID = 19581346.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC 005522; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 30CPC5LDEX / Sulfadimethoxine; 53609-64-6 / diisopropanolnitrosamine; ZF80H5GXUF / Amitrole
  • [Other-IDs] NLM/ PMC2736302
  •  go-up   go-down


59. Sassi SH, Tangour M, Mrad K, Abbes I, Amor HB, Romdhane KB: Signet-ring cell follicular adenoma of the thyroid. APMIS; 2010 Feb;118(2):165-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell follicular adenoma of the thyroid.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132181.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


60. Wang Y, Dan HJ, Dan HY, Li T, Hu B: Differential diagnosis of small single solid thyroid nodules using real-time ultrasound elastography. J Int Med Res; 2010 Mar-Apr;38(2):466-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this prospective study, the diagnostic value of real-time ultrasound elastography (USE) was evaluated in 51 consecutive patients referred for surgical treatment with single solid thyroid nodules < 10 mm in maximum diameter with an indeterminate result on B-mode and colour Doppler ultrasonography.
  • Nineteen follicular adenomas and 32 papillary thyroid microcarcinomas (PTMCs) were observed.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnostic imaging. Adenoma / diagnostic imaging. Thyroid Neoplasms / diagnostic imaging. Thyroid Nodule / diagnostic imaging. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515561.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Ito Y, Yabuta T, Hirokawa M, Fukushima M, Inoue H, Uruno T, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Miyauchi A: Distant and lymph node metastases of thyroid nodules with no pathological evidence of malignancy: a limitation of pathological examination. Endocr J; 2008 Oct;55(5):889-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among thyroid nodules arising from follicular cells, benign nodular goiter is thought not to metastasize to regional or distant organs.
  • However, we encountered five cases that were pathologically diagnosed as benign nodular goiter but showed metastasis.
  • The prevalence of benign nodular goiter showing metastasis was 0.17% (5 of 2978 patients).
  • On pathology, there were no detectable signs of carcinoma or follicular adenoma lesions.
  • Pathological diagnosis of thyroid nodules has limitations, and cases diagnosed as benign nodular goiter should still undergo careful follow-up.

  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552462.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


62. Castro I, Lima L, Seoane R, Lado-Abeal J: Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas. Thyroid; 2009 Jun;19(6):645-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
  • BACKGROUND: Two previously unreported thyrotropin (TSH) receptor mutations, A623F and I635V, were identified in toxic follicular thyroid adenoma specimens from two patients with hyperthyroidism.
  • CONCLUSIONS: A623F and I635V are two naturally occurring TSH receptor mutations that increase basal cAMP accumulation and consequently promote the development of toxic follicular thyroid adenoma. cAMP response to increasing TSH dose is retained by A623F and I635V mutated receptors and the maximal stimulation obtained is not different from that of the wild-type receptor.
  • [MeSH-major] Adenoma / genetics. Hyperthyroidism / genetics. Mutation / physiology. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / genetics

  • Genetics Home Reference. consumer health - TSHR gene.
  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499991.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Receptors, Cell Surface; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


63. Riccardi E, Grieco V, Verganti S, Finazzi M: Immunohistochemical diagnosis of canine ovarian epithelial and granulosa cell tumors. J Vet Diagn Invest; 2007 Jul;19(4):431-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Formalin-fixed, paraffin-embedded tissue sections from 4 normal ovaries, 8 granulosa cell tumors, and 6 epithelial ovarian tumors (2 adenomas and 4 adenocarcinomas) sections were obtained and stained with hematoxylin and eosin and immunohistochemically for cytokeratin AE1/AE3, cytokeratin 7, vimentin, and inhibin-alpha.
  • Granulosa cells were negative for cytokeratin 7 and displayed variable expression of vimentin, cytokeratin AE1/AE3, and inhibin-alpha toward follicular maturation.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Vet Diagn Invest. 2007 Sep;19(5):586. Greco, Valeria [corrected to Grieco, Valeria]
  • (PMID = 17609358.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 57285-09-3 / Inhibins
  •  go-up   go-down


64. Lundgren CI, Zedenius J, Skoog L: Fine-needle aspiration biopsy of benign thyroid nodules: an evidence-based review. World J Surg; 2008 Jul;32(7):1247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of benign thyroid nodules: an evidence-based review.
  • This is true also for thyroid FNAB: the vast majority of thyroid nodules are benign, and hence do not necessarily require surgical treatment.
  • The results were good, with only a few false-negative and false-positive results, but the problem of differentiating follicular adenoma from follicular carcinoma remained a significant problem.
  • [MeSH-major] Biopsy, Fine-Needle. Thyroid Gland / pathology. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2003 Summer;14(2):167-75 [12858008.001]
  • [Cites] Cytopathology. 2003 Dec;14(6):307-8 [14632726.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1410-6 [17534557.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):128-36 [12917075.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):712-8 [17151796.001]
  • [Cites] Cancer. 1997 Aug 25;81(4):253-9 [9292740.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):381-91 [17639052.001]
  • [Cites] Acta Cytol. 2001 Sep-Oct;45(5):669-74 [11575641.001]
  • [Cites] Thyroid. 2005 Mar;15(3):251-8 [15785244.001]
  • [Cites] Cancer. 2001 Aug 25;93(4):263-8 [11507700.001]
  • [Cites] Cancer. 2007 Oct 25;111(5):306-15 [17680588.001]
  • [Cites] Cytojournal. 2005 Jun 29;2(1):12 [15987502.001]
  • [Cites] Thyroid. 2001 Oct;11(10):973-6 [11716046.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Endocr Pract. 1997 Jan-Feb;3(1):9-13 [15251487.001]
  • [Cites] Cancer. 1989 Feb 15;63(4):718-25 [2914278.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Chir Ital. 2001 Sep-Oct;53(5):645-52 [11723895.001]
  • [Cites] World J Surg. 2000 Aug;24(8):907-12 [10865034.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):541-4 [9797735.001]
  • [Cites] Monogr Clin Cytol. 1974;4(0):1-211 [4600327.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] Cytopathology. 2003 Dec;14(6):327-31 [14632730.001]
  • [Cites] Surg Oncol. 2006 Dec;15(4):189-97 [17531743.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7 [12414851.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):369-73 [14739493.001]
  • [Cites] Surg Clin North Am. 1979 Feb;59(1):3-18 [441906.001]
  • [Cites] Thyroid. 2006 Oct;16(10):1003-8 [17042686.001]
  • [Cites] Thyroid. 2003 Apr;13(4):371-80 [12812214.001]
  • [Cites] Am J Surg. 1983 Jul;146(1):72-8 [6869682.001]
  • [Cites] Diagn Cytopathol. 2006 Jan;34(1):67-76 [16355378.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:3-5 [17340682.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Laryngoscope. 2006 Jan;116(1):154-6 [16481831.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Clin Lab Med. 1993 Sep;13(3):699-709 [8222583.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):48-52 [2521756.001]
  • (PMID = 18408965.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


65. Talsania N, Harwood CA, Piras D, Cerio R: Paraneoplastic Acanthosis Nigricans: The importance of exhaustive and repeated malignancy screening. Dermatol Online J; 2010;16(8):8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After exhaustive and repeated investigations a papillary thyroid carcinoma and a follicular adenoma were identified and he improved upon its resection.
  • To our knowledge, P-AN in association with thyroid neoplasm has been reported on only one previous occasion.
  • [MeSH-major] Acanthosis Nigricans / diagnosis. Adenoma / diagnosis. Carcinoma, Papillary / diagnosis. Paraneoplastic Syndromes / diagnosis. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804685.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP: Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck; 2010 Feb;32(2):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS.: In this study, 28 matched tumor and serum samples obtained from patients with both benign and malignant thyroid disorders were analyzed for BRAF mutation using a gap-ligase chain reaction technique.
  • RESULTS.: The BRAF mutation was absent in tumor DNA samples obtained from patients with benign adenomas, follicular neoplasms or carcinoma, and thyroid lymphoma.
  • Moreover, 3 of 14 patients with PTC were positive for BRAF mutation in serum and tumor.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. DNA, Neoplasm / genetics. Proto-Oncogene Proteins B-raf / blood. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Exons. Female. Hashimoto Disease. Humans. Lymphatic Metastasis. Male. Middle Aged. Mutation. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley Periodicals, Inc.
  • (PMID = 19626635.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / 1R01DE015939-01; United States / NCI NIH HHS / CA / P50 CA96784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


67. Kim JM, Ryu JS, Kim TY, Kim WB, Kwon GY, Gong G, Moon DH, Kim SC, Hong SJ, Shong YK: 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab; 2007 May;92(5):1630-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm.
  • OBJECTIVE: The objective of this study was to evaluate the usefulness of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm.
  • PATIENTS AND METHODS: A total of 46 patients with thyroid nodules larger than 1 cm in diameter cytologically diagnosed as follicular neoplasm at Asan Medical Center (Seoul, Korea) were included.
  • FDG-PET images were taken in all patients before surgical resection, and the maximum standardized uptake value (SUVmax) of each nodule was measured.
  • Fifteen patients had cancer: 11 with follicular and two each with Hürthle cell and follicular variants of papillary cancer.
  • Twenty-one patients had benign nodules: 11 follicular adenomas, eight adenomatous hyperplasias, and two Hürthle cell adenomas.
  • SUVmax did not differ significantly between malignant and benign nodules (3.6 +/- 3.5 vs. 3.4 +/- 3.2; P = 0.83) or among subtypes of benign nodules (P = 0.23).
  • CONCLUSIONS: On FDG-PET, the glucose metabolic activities of benign thyroid follicular nodules were as high as those of malignant nodules.
  • These findings suggest that FDG-PET has limited value for selecting candidates for surgery among patients cytologically diagnosed as follicular neoplasm.
  • [MeSH-major] Adenoma / radionuclide imaging. Thyroid Nodule / radionuclide imaging
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Glucose / metabolism. Humans. Male. Middle Aged. Positron-Emission Tomography. Radiopharmaceuticals

  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284624.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


68. Suzuki J, Otsuka F, Takeda M, Inagaki K, Miyoshi T, Mimura Y, Ogura T, Doihara H, Makino H: Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells. Biochem Biophys Res Commun; 2005 Feb 25;327(4):1124-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that BMP system is present in human thyroid and the expression pattern of ALK-2 and BMPRII is different between follicular adenomas and normal thyroid tissues, the endogenous BMP system may be involved in regulating thyrocyte growth and TSH sensitivity of human thyroid adenomas.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Signal Transduction / drug effects. Thyroid Gland / cytology. Thyroid Gland / drug effects. Thyrotropin / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15652513.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 0 / Receptors, Growth Factor; 67763-96-6 / Insulin-Like Growth Factor I; 9002-71-5 / Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors
  •  go-up   go-down


69. Ip YT, Dias Filho MA, Chan JK: Nuclear inclusions and pseudoinclusions: friends or foes of the surgical pathologist? Int J Surg Pathol; 2010 Dec;18(6):465-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although their recognition in the appropriate clinicopathological settings can aid in the diagnosis of some disease entities and tumor types, they can also be a source of error.
  • Nuclear pseudo-pseudoinclusions, which are artefactual bubbles in the nuclei that mimic nuclear pseudoinclusions or clear nuclei, can lead to misdiagnosis of follicular adenoma or hyperplastic nodule as papillary thyroid carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081532.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Agha A, Glockzin G, Ghali N, Iesalnieks I, Schlitt HJ: Surgical treatment of substernal goiter: an analysis of 59 patients. Surg Today; 2008;38(6):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for surgery were multinodular goiter in 46 cases, follicular adenoma in two cases, and Hashimoto's thyroiditis in one case.
  • Ten patients were operated on for recurrent thyroid disease.
  • (1) We conclude that a subtotal thyroidectomy is also the treatment of choice for asymptomatic benign substernal goiter. (2) Transverse collar incision should be the standard approach for most patients. (3) The visual identification of at least two parathyroid glands is essential to prevent permanent postoperative hypoparathyroidism.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1611-7 [9818814.001]
  • [Cites] Acta Chir Belg. 1989 Jul-Aug;89(4):206-8 [2800856.001]
  • [Cites] Ann Thorac Surg. 1985 Apr;39(4):391-9 [3885887.001]
  • [Cites] Surg Clin North Am. 1993 Aug;73(4):727-46 [8378818.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Oct;14(4):393-7 [9845144.001]
  • [Cites] Thyroid. 2002 Apr;12(4):313-7 [12034056.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):29-34 [12602531.001]
  • [Cites] Int Surg. 2003 Oct-Dec;88(4):205-10 [14717526.001]
  • [Cites] World J Surg. 1991 Mar-Apr;15(2):205-15 [2031356.001]
  • [Cites] Surg Today. 2004;34(9):732-6 [15338343.001]
  • [Cites] Am Surg. 1995 Sep;61(9):826-31 [7661484.001]
  • [Cites] Thyroid. 2005 Feb;15(2):152-7 [15753675.001]
  • [Cites] Head Neck. 2005 May;27(5):383-9 [15772954.001]
  • [Cites] Am Surg. 2002 Mar;68(3):245-51; discussion 251-2 [11893102.001]
  • [Cites] Br J Surg. 2004 May;91(5):569-74 [15122607.001]
  • [Cites] Am J Otolaryngol. 1994 Nov-Dec;15(6):409-16 [7872476.001]
  • [Cites] Int Surg. 2001 Oct-Dec;86(4):220-4 [12056465.001]
  • [Cites] Int Surg. 1999 Jul-Sep;84(3):190-2 [10533774.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 May;108(5):501-4 [10335714.001]
  • [Cites] Am J Otolaryngol. 1998 Mar-Apr;19(2):113-7 [9550443.001]
  • [Cites] Ann Chir. 1996;50(10):913-7 [9183877.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):12-7 [2045245.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1335-41 [11038203.001]
  • [Cites] World J Surg. 2001 Mar;25(3):307-10 [11343181.001]
  • [Cites] Am Surg. 1983 Apr;49(4):196-202 [6881726.001]
  • [Cites] Surgery. 2004 Dec;136(6):1310-22 [15657592.001]
  • (PMID = 18516529.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Albores-Saavedra J, Wu J: The many faces and mimics of papillary thyroid carcinoma. Endocr Pathol; 2006;17(1):1-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The follicular variants (conventional and macrofollicular) constitute a morphologic challenge because the majority of these tumors are encapsulated and, also, because, in many tumors, not all neoplastic cells show the nuclear features considered to be diagnostic of papillary carcinoma.
  • Moreover, hyperplastic thyroid lesions, follicular adenomas, and Hashimoto's thyroiditis may contain cells with clear nuclei resembling those of papillary carcinoma.
  • Papillary microcarcinomas include not only the conventional type and the follicular variants but also the tall cell and columnar cell variants.
  • [MeSH-minor] Adenoma / diagnosis. Cell Nucleus / pathology. Diagnosis, Differential. Hashimoto Disease / diagnosis. Humans. Hyperplasia / diagnosis. Thyroid Gland / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1960 Jan-Feb;9:86-97 [14400378.001]
  • [Cites] Mod Pathol. 2000 Jul;13(7):742-6 [10912933.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):810-4 [7793479.001]
  • [Cites] Am J Clin Pathol. 1988 Feb;89(2):264-7 [3341287.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):19-21 [11789725.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8 [12613443.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):77-80 [3940424.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):54-8 [11940207.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1151-5 [2227923.001]
  • [Cites] Histopathology. 1994 Dec;25(6):549-61 [7698732.001]
  • [Cites] Cancer. 1971 Sep;28(3):763-74 [5096937.001]
  • [Cites] Ann Diagn Pathol. 2003 Dec;7(6):348-53 [15018117.001]
  • [Cites] World J Surg. 1998 Jul;22(7):738-42; discussion 743 [9606291.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1110-6 [9305712.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Am J Surg Pathol. 1988 Jan;12(1):22-7 [3337337.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):416-23 [8293409.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):192-7 [8119720.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):400-11 [10229505.001]
  • [Cites] Virchows Arch. 1997 May;430(5):397-405 [9174630.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):740-53 [9477108.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):283-292 [12114789.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Am Surg. 1998 Apr;64(4):307-11 [9544139.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Mod Pathol. 1995 May;8(4):366-70 [7567932.001]
  • [Cites] Cleve Clin Q. 1976 WINTER;43(4):207-15 [1000814.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1173-9 [2302665.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1041-9 [2490923.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):964-74 [8712296.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):31-40 [12833452.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1209-15 [7573680.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] J Clin Endocrinol Metab. 1948 Sep;8(9):749-61 [18880943.001]
  • [Cites] Am J Surg Pathol. 1985 Oct;9(10):705-22 [4061729.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):301-11 [12665648.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):47-53 [9013831.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):187-92 [6703194.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1485-92 [11717537.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):297-305 [15681853.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1478-84 [11717536.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):418-24 [11956824.001]
  • [Cites] Pathol Int. 1996 Dec;46(12):939-46 [9110345.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1195-205 [1748427.001]
  • [Cites] Arch Pathol Lab Med. 1996 Apr;120(4):397-8 [8619755.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):249-51 [14615819.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):672-9 [3766846.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):95-100 [9001272.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):428-33 [8372687.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):797-807 [6660352.001]
  • [Cites] Cancer. 1966 Aug;19(8):1039-52 [5916581.001]
  • (PMID = 16760576.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


72. Benbassat CA, Mechlis-Frish S, Hirsch D: Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg; 2006 Jun;30(6):1088-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Distant metastases are seen in a minority of patients with differentiated thyroid carcinoma (DTC) but account for most of its disease-specific mortality.
  • Forty-four patients (6.7%) had distant metastases, with a prevalence of 4.8% for papillary thyroid cancer, 21% for follicular thyroid cancer, and 10% for Hurthle cell cancer.
  • RESULTS: The distant metastasis occurred synchronously with the primary tumor in 45.5% and after a median follow-up of 9 years in the others.
  • CONCLUSIONS: We conclude that complete resection of the thyroid gland at diagnosis and high-dose adjuvant radioactive iodine are associated with improved survival in patients with metastatic DTC.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Rate. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2007 Jan;31(1):246-7; author reply 247-8 [17180558.001]
  • [Cites] Tumori. 1991 Oct 31;77(5):432-6 [1781039.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):960-7 [3745409.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):283-90 [2312106.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):600-4 [7725751.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):501-8 [3410936.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):685-718 [2261912.001]
  • [Cites] World J Surg. 2002 Feb;26(2):153-7 [11865341.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):87-93 [15963067.001]
  • [Cites] Arch Surg. 1989 Dec;124(12):1374-7 [2589960.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5303-7 [15531474.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63 [11297567.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):713-20 [9497879.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1227-35 [10646663.001]
  • [Cites] Surgery. 1999 Dec;126(6):1173-81; discussion 1181-2 [10598204.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4043-9 [10566647.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):191-7 [12892796.001]
  • [Cites] Surgery. 1989 Dec;106(6):960-6 [2588123.001]
  • [Cites] J Nucl Med. 1996 Apr;37(4):598-605 [8691248.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2041-5 [7608252.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1762-8 [12175693.001]
  • (PMID = 16736341.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL: Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol; 2008 Oct;15(10):2811-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this work was to evaluate the molecular phenotype of differentiated thyroid cancer (DTC) and benign thyroid lesions to identify molecular markers that allow for accurate thyroid cancer diagnosis.
  • METHODS: Tissue microarrays consisting of 100 benign and 105 malignant thyroid lesions, plus 24 lymph node samples, were stained for a panel of 57 molecular markers.
  • Significant associations between marker staining and tumor pathology (DTC versus benign) were determined using contingency table and Mann-Whitney U (MU) tests.
  • Of these, in DTC compared with benign thyroid tumors, 8 markers were downregulated and 27 upregulated.
  • Using the entire molecular marker panel, a Random Forests algorithm was able to classify tumors as DTC or benign with an estimated sensitivity of 87.9%, specificity of 94.0%, and an accuracy of 91.0%.
  • CONCLUSION: Evaluation of the DTC and benign thyroid tumor molecular phenotype has allowed for identification of a marker panel, composed of both established and novel markers, useful for thyroid cancer diagnosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Cell Differentiation. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Phenotype. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612701.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Hunt JL, Yim JH, Carty SE: Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors. Thyroid; 2006 Jul;16(7):643-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors.
  • Thyroid follicular tumors can be challenging diagnostically and clinically, because the cytologic and histologic features can be subtle and prognosis is also difficult to predict.
  • In this study, we analyzed thyroid follicular tumors with known long-term follow-up for a molecular panel of tumor suppressor genes to determine whether this molecular approach has prognostic significance.
  • Microdissection and DNA extraction were performed from tumor and normal tissue.
  • Polymerase chain reaction (PCR) was performed for 13 short tandem repeats at or near tumor suppressor genes.
  • We included eight adenomas, three minimally invasive carcinomas, four angioinvasive carcinomas, and three widely invasive carcinomas with a mean follow-up of 77 months.
  • Three patients died of disease and an additional two are alive with disease recurrence/metastasis.
  • The mean FAL for benign tumors (14%) was significantly different from that of malignant tumors (56%, p < 0.001).
  • Patients with a follicular tumor who had no evidence of disease recurrence had a mean FAL of 22% and those with disease recurrence or death from disease had a mean of 78% (p < 0.002).
  • Based on these results, a tumor suppressor gene panel for allelic imbalance in follicular-derived tumors (FTT) may correlate with both malignancy and outcome in patients with follicular-derived carcinomas of the thyroid.
  • [MeSH-major] Adenoma / genetics. Adenoma / therapy. Carcinoma / genetics. Carcinoma / therapy. Genes, Tumor Suppressor. Loss of Heterozygosity. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889487.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 9007-49-2 / DNA
  •  go-up   go-down


75. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C: Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid; 2005 Jul;15(7):708-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid nodule is common disorder in endocrine clinics.
  • Of patients undergoing surgical treatment, 2761 (76.1%) patients were diagnosed with benign nodules, 858 (23.6%) with malignant nodules, and 10 (0.3%) with atypical adenoma (7 follicular and 3 Hürthle cells).
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / ultrasonography. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Medullary / epidemiology. Carcinoma, Medullary / pathology. Carcinoma, Medullary / ultrasonography. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Retrospective Studies. Risk Factors. Sex Distribution

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053388.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Krause K, Karger S, Schierhorn A, Poncin S, Many MC, Fuhrer D: Proteomic profiling of cold thyroid nodules. Endocrinology; 2007 Apr;148(4):1754-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cold thyroid nodules (CTNs) represent a frequent endocrine disorder accounting for up to 85% of thyroid nodules in a population living in an iodine-deficient area.
  • Benign CTNs need to be distinguished from thyroid cancer, which is relatively rare.
  • The molecular etiology of benign CTNs is unresolved.
  • To obtain novel insights into their pathogenesis, protein expression profiling was performed in a series of 27 solitary CTNs (10 follicular adenoma and 20 adenomatous nodules) and surrounding normal thyroid tissues using two-dimensional gel electrophoresis combined with mass spectrometry analysis, Western blotting, and immunohistochemistry.
  • Furthermore, we provide preliminary evidence that up-regulation of H2O2 generation in CTNs could override the antioxidative system resulting in oxidative stress, which is suggested by the finding of raised 8-oxo-guanidine DNA adduct formation in CTNs.


77. Delbridge L: Solitary thyroid nodule: current management. ANZ J Surg; 2006 May;76(5):381-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority are benign with thyroid cancer representing an uncommon clinical problem.
  • Because it is not possible to distinguish a follicular carcinoma from a follicular adenoma on cytological grounds alone, this category must simply be interpreted as indicating a follicular tumour and up to 20% will be malignant.
  • Hemithyroidectomy via a 'collar' incision, with submission of the specimen to formal pathological examination, remains the standard of care, with completion total thyroidectomy for cancers other than low risk papillary cancer and 'minimally invasive' follicular cancer without vascular invasion.
  • The issue of whether follicular adenomas can potentially develop into follicular carcinomas has yet to be satisfactorily resolved.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768700.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 42
  •  go-up   go-down


78. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA: Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid; 2009 Feb;19(2):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).
  • BACKGROUND: Encapsulated papillary thyroid carcinoma (EPTC) can have a histologic growth pattern similar to the one seen in classical papillary thyroid carcinoma (PTC) or akin to the follicular variant of PTC (FVPTC).
  • All 34 noninvasive E-FVPTC lacked evidence of nodal metastases while 4 of 15 (27%) noninvasive E-CPTC presented with nodal disease (p = 0.006).
  • These four FVPTC had extensive capsular and/or vascular invasion and no nodal disease.
  • CONCLUSION: E-CPTC resembles classical PTC in its propensity to metastasize to lymph nodes and its vascular/capsular invasive pattern while E-FVPTC behaves more like follicular carcinoma/adenoma group of tumors.
  • Noninvasive E-FVPTC could be managed like minimally invasive follicular carcinoma by lobectomy without RAI therapy.
  • [MeSH-major] Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adult. Aged, 80 and over. Carcinoma, Papillary / pathology. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Retrospective Studies. Treatment Outcome


79. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M, Motti ML, Pasquinelli R, Agosti V, Robledo M, Fusco A, Viglietto G: Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer; 2007 Jun;14(2):405-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry analysis showed that Skp2 was overexpressed significantly in thyroid carcinomas (26 out of 51) compared with goitres (0 out of 12, P<0.001) or adenomas (1 out of 10, P<0.05), and that high Skp2 expression was detected more often in anaplastic thyroid (ATC; 83%, n=12) than follicular thyroid (FTC; 40%, n=20) or papillary thyroid (PTC; 42%, n=19) carcinomas (P<0.05).
  • [MeSH-minor] Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Amplification. Humans. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639054.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S-Phase Kinase-Associated Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


80. Candela G, Varriale S, Di Libero L, Maschio A, Giordano M, Manetta F, Sullo P, Casaburi V, Lanza M, Santini L: [Nearly total thyroidectomy: versus total thyroidectomy: our experience]. Minerva Chir; 2006 Feb;61(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Generally, the classification of thyroidectomy as benign pathology is: multinodular toxic goitre, simple goitre, toxic adenoma, Base-dow disease, Hashimoto's tyroiditis Subtotal thyroidectomy provides for the removal of the gland except for a bilateral residue of about 6-10 g, near total thyroidectomy provides for the near total removal of the gland except for a residue inferior to 5 grams.
  • METHODS: In two years, in our institute, there have been exeuted: 96 near total thyrodectomies, 96 total thyroidetomies, 8 lobectomies ad two revues for recurrencies.
  • Only in 1 case we practiced tracheotomy for follicular carcinoma infiltering thiroidic cartilage.
  • Even if the surgical approach to the benign disease is now orientated to the total thyroidectomy, a more conservative surgery is, in our opinion, justified when a malignant pathology is excluded and considering also the low effect of recurrencies and hypothyroidism.

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568018.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Ganguly R, Mitra S, Datta AK: Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):337-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland.
  • Various combinations of thyroid carcinomas have been reported including those between different cancers of follicular cell origin and those between follicular and C-cell histogenesis.
  • Accordingly, anaplastic carcinomas have been seen to coincide with simultaneous papillary and follicular cancers.
  • We report a case of composite anaplastic and papillary cancer on one thyroid lobe with a follicular carcinoma in the other lobe in a female patient aged 64 years.
  • The patient also had a separate and independent follicular adenoma in the same lobe as the composite anaplastic and papillary carcinoma.
  • The common follicular cell origin will explain the concurrent presence of all these cancers.
  • This could result from the dedifferentiation of a pre-existing differentiated carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / complications. Adenoma / complications. Carcinoma / complications. Carcinoma, Papillary / complications. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):434-5 [21623130.001]
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):414-5; author reply 415 [21623114.001]
  • (PMID = 20551551.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


82. Tsilchorozidou T, Vafiadou E, Yovos JG, Romeo G, McKay J, Lesueur F, Bonora E: A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Thyroid; 2005 Dec;15(12):1349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
  • The majority of FNMTC pedigrees are small in size, show variable modes of inheritance, and may present with a variety of additional benign thyroid disorders.
  • This locus appears particular relevant to families with at least one case of the follicular variant of papillary thyroid cancer (fvPTC).
  • We describe the clinical and pathologic characteristics of a large three-generation fPTC kindred, with two of the four PTC patients presented with the follicular variant of PTC.
  • In addition, multinodular goiter (MNG) was diagnosed in seven individuals, lymphocytic thyroiditis in four, while one diagnosed with a benign adenoma.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Genetic Predisposition to Disease. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405407.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Tömböl Z, Szabó P, Rácz K, Tulassay Z, Igaz P: [Relevance of microRNA-s in neoplastic diseases]. Orv Hetil; 2007 Jun 17;148(24):1135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MicroRNA profiles enable the distinction of benign follicular adenomas from follicular neoplasms of the thyroid.
  • [MeSH-major] MicroRNAs / metabolism. Neoplasms / genetics. RNA Interference. RNA, Neoplasm / metabolism. RNA, Small Interfering / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561483.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering
  • [Number-of-references] 50
  •  go-up   go-down


84. Dzodic R, Markovic I, Inic M, Jokic N, Djurisic I, Zegarac M, Pupic G, Milovanovic Z, Jovic V, Jovanovic N: Sentinel lymph node biopsy may be used to support the decision to perform modified radical neck dissection in differentiated thyroid carcinoma. World J Surg; 2006 May;30(5):841-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognostic significance of lymph node metastases (LNM) in follicle cell-derived differentiated thyroid carcinoma (DTC) is still controversial.
  • The specificity of the method was 100%, sensitivity 77.7%, negative predictive value 94%, positive predictive value 100%, with overall accuracy of 95%.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] World J Surg. 2006 May;30(5):918. Markovic, Ivan [added]; Inic, Momcilo [added]; Jokic, Neven [added]; Djurisic, Igor [added]; Zegarac, Milan [added]; Pupic, Gordana [added]; Milovanovic, Zorka [added]; Jovic, Viktor [added]; Jovanovic, Nikola [added]
  • [Cites] World J Surg. 1999 Sep;23(9):970-3; discussion 973-4 [10449830.001]
  • [Cites] Asian J Surg. 2003 Jul;26(3):145-8 [12925288.001]
  • [Cites] Cancer Control. 2000 May-Jun;7(3):240-5 [10832110.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1234-41 [1997164.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):21-4; discussion 25 [11344476.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):251-61 [3551147.001]
  • [Cites] Endocr Pract. 2000 Nov-Dec;6(6):469-76 [11155222.001]
  • [Cites] Ann Radiol (Paris). 1977 Nov-Dec;20(8):767-70 [610546.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1396-401 [11038213.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:100s-103s [12487263.001]
  • [Cites] Surgery. 2001 Sep;130(3):439-42 [11562667.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):315-24 [3281847.001]
  • [Cites] Arch Surg. 1990 Jun;125(6):804-6 [2346381.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):559-67; discussion 567-8 [7725745.001]
  • [Cites] World J Surg. 1988 Dec;12(6):825-9 [3250133.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):242-7 [12679308.001]
  • [Cites] Surg Oncol. 2002 Nov;11(3):137-42 [12356509.001]
  • [Cites] Surgery. 2001 Dec;130(6):907-13 [11742316.001]
  • [Cites] Surgery. 1998 Dec;124(6):947-57 [9854568.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):276-80 [9517740.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1194-8; discussion 1199 [11030879.001]
  • [Cites] Surg Oncol. 1993 Dec;2(6):335-9; discussion 340 [8130940.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2868-74 [11753960.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):794-804 [3967174.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):288-92 [9517742.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):353-6 [1951888.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • (PMID = 16680598.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Veroux M, Giuffrida G, Gagliano M, Giaquinta A, Tallarita T, Sorbello M, Corona D, Zerbo D, Vizcarra D, Scriffignano V, Cannizzaro MA, Veroux P: Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up. Transplant Proc; 2009 May;41(4):1142-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up.
  • INTRODUCTION: Diagnosis of thyroid disease is fundamental in the evaluation of patients awaiting kidney transplantation.
  • We analyzed the incidence of thyroid disease in patients with end-stage renal disease (ESRD) and evaluated its evolution before and after kidney transplantation.
  • RESULTS: One-hundred-four patients with ESRD (44%) had functional or morphologic changes in the thyroid gland.
  • Forty-one patients (17.4%) underwent fine-needle aspiration cytology; 3 demonstrated showed papillary carcinoma; 3, follicular adenomas; 8, uncertain cytologic lesions; and 27, a nodular goiter.
  • Of the 184 transplant recipients, 10 underwent surgery to treat thyroid disease: 8 with multinodular goiter, 1 with micropapillary carcinoma, and 1 with follicular adenoma.
  • All 10 patients are alive with a well-functioning graft and no signs of disease recurrence.
  • [MeSH-major] Carcinoma, Papillary / complications. Kidney Failure, Chronic / surgery. Kidney Transplantation. Neoplasm Recurrence, Local / complications. Thyroid Neoplasms / epidemiology


86. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol; 2006 Feb;154(2):341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, its prevalence is varyingly reported in different studies, and its expression in the follicular variant PTC is controversial, reducing its potential usefulness as diagnostic marker.
  • Then, we used MASA 78 to analyze 78 archival thyroid tissues, including normal samples, follicular adenomas, follicular carcinomas and PTC.
  • BRAF mutation was found by MASA in 19/43 (44.2%) of PTC, including 14/31 (45.2%) classic forms and 5/12 (41.7%) follicular variants.
  • No mutations of BRAF were detected in the normal thyroid tissues, nor in follicular adenomas or follicular carcinomas.
  • CONCLUSIONS: BRAF(V600E) is present in PTC, both in the classic form and in follicular variant with similar prevalence.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452550.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


87. Kazakov DV, Bisceglia M, Calonje E, Hantschke M, Kutzner H, Mentzel T, Michal M, Mukensnabl P, Spagnolo DV, Rütten A, Rose C, Urso C, Vazmitel M, Zelger B: Tubular adenoma and syringocystadenoma papilliferum: a reappraisal of their relationship. An interobserver study of a series, by a panel of dermatopathologists. Am J Dermatopathol; 2007 Jun;29(3):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular adenoma and syringocystadenoma papilliferum: a reappraisal of their relationship. An interobserver study of a series, by a panel of dermatopathologists.
  • Tubular adenoma (TA) and syringocystadenoma papilliferum (SCAP) may show histopathological overlap, with some lesions having features of both neoplasms (SCAP + TA).
  • Four observers blindly assessed 67 cases of TA, SCAP, and their lookalikes (poroma, apocrine adenoma, apocrine carcinoma; all lesions focally featuring a pseudopapillary pattern), and classified the lesions into one of four categories:.
  • Lesions were also classified as benign or malignant.
  • Analysis of the factors leading to interobserver variability indicated that diagnostic problems occurred when there were any of the following: epidermal acanthosis, papillomatosis, connection of the neoplastic tubules to the overlying epidermis and/or follicular infundibula, and plasma cell infiltration.
  • All observers agreed that the lesions were benign; the only apocrine carcinoma included was recognized as such by all observers.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Cystadenoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sweat Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Syringocystadenoma papilliferum.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519623.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


88. Elgadi A, Frisk T, Larsson C, Wallin G, Höög A, Zedenius J, Norgren S: Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease. Exp Clin Endocrinol Diabetes; 2005 Oct;113(9):516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease.
  • The aim of this study was to investigate whether TSHr antibody negative Graves' disease is associated with somatic mutations in the TSHr or Gsalpha genes and whether histopathologically defined thyroid lesions, i.e., hyperfunctioning adenoma, non-functioning follicular adenomas, or nodules in toxic and non-toxic multinodular goiters are associated with such mutations.
  • No mutations but three germ-line polymorphisms were found in patients with TSHr antibody negative Graves' disease.
  • Two heterozygous somatic TSHr mutations were found in two hyperfunctioning adenomas and in two toxic multinodular goiters.
  • The lack of TSHr and Gsalpha mutations in TSHr antibody negative Graves' disease patients indicates that such mutations are neither primary nor secondary events in this disease.
  • The results also confirm that somatic gain-of-function TSHr mutations are present in hyperfunctioning follicular adenomas and goiters, but not in non-functioning thyroid lesions.
  • [MeSH-major] Autoantibodies. GTP-Binding Protein alpha Subunits, Gs / genetics. Graves Disease / genetics. Mutation. Polymorphism, Genetic. Receptors, Thyrotropin / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / immunology. Adult. Aged. DNA Mutational Analysis / methods. Exons / genetics. Female. Goiter, Nodular / genetics. Goiter, Nodular / immunology. Humans. Male. Middle Aged. Signal Transduction / genetics. Signal Transduction / immunology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / immunology

  • Genetic Alliance. consumer health - Graves' Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235153.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Receptors, Thyrotropin; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


89. Ota Y, Imai T, Onose J, Takami S, Cho YM, Hirose M, Nishikawa A: A 55-week chronic toxicity study of dietary administered kojic acid (KA) in male F344 rats. J Toxicol Sci; 2009 Jun;34(3):305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the thyroids, diffuse follicular cell hyperplasia at 0.5 and 2.0% and focal follicular cell hyperplasia and follicular adenoma at 2.0% were increased.
  • A thyroid follicular carcinoma was also observed at 2.0%.
  • [MeSH-minor] Administration, Oral. Animal Feed. Animals. Body Weight / drug effects. Cell Enlargement / drug effects. Eating / drug effects. Erythrocyte Count. Hematocrit. Hepatocytes / drug effects. Hepatocytes / pathology. Hypertrophy / chemically induced. Hypertrophy / pathology. Male. Necrosis / chemically induced. Necrosis / pathology. No-Observed-Adverse-Effect Level. Organ Size / drug effects. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Rats. Rats, Inbred F344. Thyroid Gland / drug effects. Thyroid Gland / pathology. Toxicity Tests, Chronic. gamma-Glutamyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483384.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Food Additives; 0 / Pyrones; 6K23F1TT52 / kojic acid; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


90. Foschini MP, Ragazzi M, Parmeggiani AL, Righi A, Flamminio F, Meringolo D, Castaldini L: Comparison between echo-color Doppler sonography features and angioarchitecture of thyroid nodules. Int J Surg Pathol; 2007 Apr;15(2):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type II and III nodules corresponded to colloid goiter with intralesional hemorrhage or were associated with hyperplastic nodules, follicular adenoma, follicular carcinoma minimally invasive, papillary carcinoma, and medullary carcinoma.
  • Of interest was that 9 of 11 follicular lesions were characterized by a large central vessel, which was also evident in echo-color Doppler images.
  • This architectural pattern is not seen in benign nodules or in papillary carcinomas.
  • [MeSH-major] Imaging, Three-Dimensional. Thyroid Gland / ultrasonography. Thyroid Nodule / ultrasonography. Ultrasonography, Doppler, Color / methods
  • [MeSH-minor] Adenoma / pathology. Adult. Aged. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Female. Goiter, Nodular / pathology. Humans. Male. Middle Aged. Preoperative Care. Thyroid Neoplasms / pathology. Thyroidectomy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478766.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Liu FH, Liou MJ, Hsueh C, Chao TC, Lin JD: Thyroid follicular neoplasm: analysis by fine needle aspiration cytology, frozen section, and histopathology. Diagn Cytopathol; 2010 Nov;38(11):801-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular neoplasm: analysis by fine needle aspiration cytology, frozen section, and histopathology.
  • We performed a retrospective analysis of follicular neoplasm data obtained from frozen section examinations of thyroid nodules.
  • In 971 cases, frozen section examination was performed during the surgical treatment of follicular neoplasm that was diagnosed via FNAC.
  • Among the patients with papillary thyroid carcinoma, 45 were diagnosed with the follicular variant of papillary thyroid carcinomas (27.4%).
  • The diagnostic sensitivity of frozen section for the nonfollicular variant of papillary thyroid carcinoma was better than that for the follicular variant of papillary thyroid carcinoma (89.1% versus 78.9%; P = 0.1023).
  • For 12 cases the diagnosis was atypical follicular adenomas.
  • The diagnostic accuracy of frozen section in cases of follicular neoplasm was 76.9% with a sensitivity of 84.8% and a specificity of 98.9%.
  • In conclusion, our analysis revealed high rates of accuracy when using frozen tissue sections for early diagnosis and treatment of follicular neoplasm; thus, an early decision to extent of surgery prevents a risky follow-up surgery.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Frozen Sections. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Wiley-Liss, Inc.
  • (PMID = 20014303.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Kessler A, Gavriel H, Zahav S, Vaiman M, Shlamkovitch N, Segal S, Eviatar E: Accuracy and consistency of fine-needle aspiration biopsy in the diagnosis and management of solitary thyroid nodules. Isr Med Assoc J; 2005 Jun;7(6):371-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the sensitivity, specificity, accuracy, and positive and negative predictive values of FNAB in cases of a solitary thyroid nodule.
  • RESULTS: In cases of a solitary thyroid nodule, FNAB had a sensitivity of 79%, specificity of 98.5%, accuracy of 87%, and positive and negative predictive values of 98.75% and 76.6% respectively.
  • All cases of papillary carcinoma diagnosed by FNAB proved to be malignant on final histology, while 8 of 27 cases of follicular adenoma detected by preoperative FNAB were shown to be malignant on final evaluation of the surgical specimen.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Israel / epidemiology. Male. Middle Aged. Predictive Value of Tests. Preoperative Care. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Isr Med Assoc J. 2005 Sep;7(9):616; author reply 616 [16190494.001]
  • (PMID = 15984379.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


93. Garcia EA, Simões K, Wakamatsu A, Ressio RA, Alves VA, Longatto-Filho A, Camargo RS: Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol; 2010 Jun;21(2):101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions.
  • Thyroid cancer is the most frequent endocrine neoplasia worldwide.
  • In order to evaluate the value of LVD in benign and malignant thyroid lesions, we analyzed 110 thyroidectomy specimens using D2-40, a specific marker for lymphatic vessels and vascular endothelial growth factor C (VEGF-C), the most potent molecule of lymphatic proliferation.
  • LVD was significantly different between papillary and follicular carcinomas in total (p = 0.045) and peritumoral area (p = 0.042).
  • Follicular adenoma and follicular carcinoma showed an important difference of intra- (p = 0.019) and peritumoral (p = 0.033) LVD.
  • VEGF-C was more markedly expressed in malignancies than in benign lesions (p = 0.0001).
  • Almost all cancers with high positive VEGF-C expression also exhibited increased peritumoral LVD (p = 0.049) when compared with the benign lesions.
  • Indeed, the high peritumoral LVD of malignant thyroid lesions is an important finding for surgery planning and supports the practice of total thyroidectomy in malignant thyroid neoplasm's since the lymphatic peritumoral vessels definitely are an escape path for tumor cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphatic Vessels / pathology. Thyroid Neoplasms / pathology. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):730-8 [17103065.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8364-71 [16322297.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):45-51 [17604828.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):426-30 [12888807.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):777-94 [16364190.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8413-20 [15623620.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1315-20 [11888898.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):171-80 [12539171.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7144-9 [15534085.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1424-31 [15920537.001]
  • [Cites] Histopathology. 2009 Nov;55(5):514-24 [19912357.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):640-5 [1463115.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1611-25 [17117184.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Physiol Rev. 2002 Jul;82(3):673-700 [12087132.001]
  • [Cites] Mol Divers. 2006 Nov;10(4):515-27 [16972015.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):133-8 [18087718.001]
  • [Cites] Pharmacol Ther. 2009 Jul;123(1):117-41 [19374919.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Jun;27(3):157-61 [16121637.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • (PMID = 20336393.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C; 0 / monoclonal antibody D2-40
  •  go-up   go-down


94. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M: Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers? Neoplasma; 2007;54(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A semi-quantitative RT-PCR assay was developed to determine prothymosin alpha and parathymosin mRNA expression patterns in thyroid follicular cells obtained from the fine-needle aspiration biopsy specimens of patients diagnosed with simple nodular goitre, follicular adenoma, papillary and follicular well-differentiated carcinomas.
  • Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
  • Further studies are required to establish prothymosin alpha and parathymosin as diagnostic proliferation markers in thyroid cancer, especially in cases of undetermined cellular morphology of follicular origin which reflect the most common cytohistopathological discrepancies.
  • [MeSH-major] Protein Precursors / genetics. Thymosin / analogs & derivatives. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. Biomarkers / analysis. Biopsy, Fine-Needle / methods. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203893.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / prothymosin alpha; 61512-21-8 / Thymosin; 95328-48-6 / parathymosin alpha
  •  go-up   go-down


95. Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF: Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst; 2008 Mar;20(1):36-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Galectin-3 is a human lectin linked to malignant transformation in different organs including thyroid gland.
  • We aimed to evaluate the diagnostic role of galectin-3 in differentiating benign from malignant thyroid lesions in cytological and histological samples.
  • MATERIAL AND METHODS: This study included a total of 79 cases; 19 multinodular goiter (MNG), 19 follicular adenoma (FA), 13 follicular carcinoma (FTC) and 28 papillary carcinoma (PTC).
  • According to H score, glaectin-3 immunostaining was significantly lowered in FA) 1+/-2.8 as compared to papillary (158.5+/-88.6) and follicular carcinoma (150+/-83.9) (p>0.0001).
  • However, there was no statistically significant difference between FTC and PTC (p=0.56) or between classic and follicular variants of PTC (p=0.51).
  • Prospective analysis: There were five benign, six malignant and 17 indeterminate cytology cases.
  • Galectin-3 immunostaining was able to detect the benign nature of 11/17 indeterminate cytology.
  • Combination of standard cytological evaluation with galectin-3 immunostaining markedly improved sensitivity (71% versus 85%), specificity (75% versus 94%), positive predictive value (83% versus 92%) negative predictive value (60% versus 87.5%) and diagnostic accuracy (72% versus 90%).
  • CONCLUSION: We suggest Galectin-3 as a supplementary immunostaining in histological diagnosis of difficult thyroid follicular lesions and in preoperative evaluation of indeterminate thyroid cytology to avoid unnecessary aggressive surgical interference in benign lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847280.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


96. Bosco M, Galliano D, La Saponara F, Pacchioni D, Bussolati G: Cytologic features of metanephric adenoma of the kidney during pregnancy: a case report. Acta Cytol; 2007 May-Jun;51(3):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of metanephric adenoma of the kidney during pregnancy: a case report.
  • BACKGROUND: Metanephric adenoma (MA) is a relatively rare neoplasm derived from metanephric blastema and composed of well-differentiated epithelial nephroblastic cells.
  • In view of its invariably benign clinical outcome, a preoperative diagnosis of this tumor could be of critical importance.
  • Since computed tomography and ultrasound imaging are not per se sufficient to unequivocally distinguish between MA and malignant neoplasms, fine needle aspiration cytology (FNAC) could be the only accurate method to establish a preoperative diagnosis of this tumor.
  • FNA smears showed small, uniform cells with bland nuclei arranged in compact acinar and follicular structures; immunocytochemical staining revealed a diffuse, positive reaction for CD57, WT-1 and vimentin, and epithelial membrane antigen and alpha-methylacyl-CoA racemase yielded negative results.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536558.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Koh YW, Kim JW, Lee SW, Choi EC: Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc; 2009 Sep;23(9):2053-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions.
  • A skin incision parallel to the skin crease was made in the axillary fossa for insertion of a 10-mm 30 degrees rigid endoscope and endoscopic instruments.
  • A second 1.0-cm skin incision was made along the upper margin of the mammary areola on the tumor side for insertion of a 12-mm trocar.
  • RESULTS: Postoperative pathology showed 11 follicular adenomas, 1 follicular carcinoma, and 40 benign thyroid lesions.
  • CONCLUSION: Although the aspect of invasiveness could be improved, endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation is safe and effective and appears to provide better cosmetic results and a shorter operation time than other endoscopic methods for managing selective unilateral benign thyroid lesions.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Thyroid Diseases / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Axilla. Breast. Drainage. Feasibility Studies. Female. Hematoma / etiology. Humans. Length of Stay. Male. Middle Aged. Postoperative Complications / etiology. Seroma / etiology. Vocal Cord Paralysis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Jan;22(1):154-7 [17440778.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):226-31 [16921301.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12):2166-71 [17479328.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):286-9 [11943128.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]
  • [Cites] Surgery. 1997 Nov;122(5):893-901 [9369889.001]
  • [Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] World J Surg. 2007 Mar;31(3):601-6 [17308853.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2007 Feb;17(1):21-5 [17362173.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] J Surg Oncol. 1994 Dec;57(4):235-8 [7990478.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2302-6; discussion 2307-8 [17566819.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):268-72 [11525373.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):697-703 [10359365.001]
  • (PMID = 18528625.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Gyory F, Mezosi E, Szakall S, Bajnok L, Varga E, Borbely A, Gazdag A, Juhasz I, Lukacs G, Nagy EV: Establishment of the hu-PBL-SCID mouse model for the investigation of thyroid cancer. Exp Clin Endocrinol Diabetes; 2005 Jul;113(7):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New experimental models of human neoplastic diseases attempt to mimic the human environment that fostered the development of disease in cancer patients.
  • Thyroid neoplastic tissues were obtained from ten patients (one follicular adenoma, five papillary, one follicular, one anaplastic and two medullary cancers).
  • One 8 x 4 x 3 millimeter sample from each tumor was cut into two pieces of identical size and transplanted into two SCID mice.
  • In each case, one of the two mice was injected intraperitoneally with lymphocytes from the same tumor patient for the reconstitution of the human immune system (Group A), while the other animal received no lymphocytes (Group B).
  • When histologies were compared before implantation and after the removal of the implants, the characters of the tumors proved to be unchanged, except one case where an anaplastic cancer arose from a papillary tumor.
  • In conclusion, an animal model has been established for the investigation of human thyroid cancer, by which the analysis of anti-tumor immunity, as a postulate of immune therapy, may be possible.
  • [MeSH-major] Disease Models, Animal. Lymphocytes / immunology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Animals. Antigens, CD / blood. Antigens, CD / immunology. Female. HLA-DR Antigens / blood. Humans. Immunoglobulin M / blood. Immunohistochemistry. Immunotherapy. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Transplantation. Thyroglobulin / blood. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025395.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens; 0 / Immunoglobulin M; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


99. Fuhrer D, Eszlinger M, Karger S, Krause K, Engelhardt C, Hasenclever D, Dralle H, Paschke R: Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. Eur J Endocrinol; 2005 May;152(5):785-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
  • OBJECTIVE: We evaluated three markers (insulin-like growth factor II (IGF-II), cyclooxygenase-2 (COX-2) and ets-1) of thyroid growth stimulation and cell transformation together with a thyroid-specific marker (thyroglobulin (Tg)) for their potential to differentiate benign and malignant follicular thyroid neoplasia (FN).
  • DESIGN AND METHODS: mRNA expression levels were determined by real-time PCR in 100 snap-frozen thyroid samples: 36 benign thyroid nodules with different histology and function (19 cold (CTN) and 17 toxic thyroid nodules (TTN)), 36 corresponding normal thyroid tissues of the same patients, eight Graves' disease (GD) thyroids, 10 follicular thyroid carcinomas (FTC) and 10 papillary thyroid carcinomas (PTC).
  • RESULTS: Mean IGF-II and COX-2 levels were not significantly altered between benign and malignant thyroid nodules (IGF-II) or nodular (FTC, TTN, CTN) and normal thyroid tissues (COX-2).
  • In contrast, eight- to tenfold upregulation of ets-1 was observed in PTC and three- to fourfold upregulation of ets-1 was observed in FTC (and GD) compared with benign thyroid nodules and normal thyroid tissues.
  • In addition, thyroglobulin mRNA expression was markedly downregulated (50- to 100-fold) in FTC, PTC and GD samples compared with benign nodular and normal thyroid tissues.
  • Hence an ets-1/Tg ratio >20 distinguished differentiated thyroid cancer from benign nodular or normal thyroid tissue.
  • However, in a consecutive series of 40 FNAC samples only equivocal results were obtained on 38 benign and two malignant (FTC) thyroid tumour samples.
  • CONCLUSIONS: Upregulation of ets-1 and downregulation of Tg mRNA expression occur in differentiated thyroid cancer and may facilitate pre-operative identification of thyroid malignancy depending on further evaluation of these potentially promising markers in a larger series of benign and malignant thyroid tumours and their FNAC samples.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879365.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ETS1 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Transcription Factors; 67763-97-7 / Insulin-Like Growth Factor II; 9010-34-8 / Thyroglobulin; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


100. Puskas LG, Juhasz F, Zarva A, Hackler L Jr, Farid NR: Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand); 2005 Sep 5;51(2):177-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies done to date have concentrated on single tumor types and thus provide no help in identifying tumor subtype specific markers.
  • To that end we have studied gene profiles of 5 types of benign and malignant thyroid nodular tissue (multinodular goiter, follicular adenoma, papillary and follicular carcinomas).
  • Despite the differences in the microarray panels used, we confirmed the differential regulation of 12 genes previously reported in thyroid cancer, although we found the expression of several genes to be regulated in other histological tumor subtypes than originally described.
  • We found, PCSK2, TRIB1, RAP1 GA1 to be specifically overexpressed in follicular cancer and S100A4 and GK2 in papillary carcinoma.
  • It is apparent that a range of nodular thyroid tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples.
  • [MeSH-major] Gene Expression Profiling. Genes, Neoplasm. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / physiopathology. Adenoma / diagnosis. Adenoma / genetics. Adenoma / physiopathology. Biomarkers, Tumor / genetics. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / physiopathology. Gene Expression Regulation, Neoplastic. Goiter, Nodular / diagnosis. Goiter, Nodular / genetics. Goiter, Nodular / physiopathology. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171553.001).
  • [ISSN] 1165-158X
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement